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 Chronic obstructive pulmonary disease (COPD) is currently the third leading 
cause of death in the United States with continuously elevating morbidity and mortality. 
COPD is a complex progressive disease primarily caused by cigarette smoke (CS) as well 
as other inhaled pollutants. The disease is characterized by chronic, irreversible 
obstruction of airflow from the lung, which is resulted from both airspace enlargement 
(i.e. emphysema), as well as airway inflammation, remodeling, and mucus hypersecretion 
(chronic bronchitis).  
Perturbations in the properties of airway mucus contribute to accelerated lung 
function decline in patients with COPD, which leads to reduced quality of life and an 
elevated mortality rate. Alterations in the bulk physicochemical properties of mucus have 
been widely investigated in an attempt to unravel key factors affecting disease severity. 
Nonetheless, microstructural characteristics of mucus have not yet been explored in 
COPD. I first investigated whether the mesh size of spontaneously expectorated COPD 
sputum, as indicated by muco-inert nanoparticle diffusion, correlated with impaired lung 
function and altered sputum composition. I found that the diffusion of 100 nm muco-inert 
nanoparticles could sensitively differentiate microstructural features of sputum samples 
from cigarette smokers without airway obstruction and COPD patients. Nanoparticle 
mobility correlated with measurements of lung function as well as sputum solids and 
mucin content. These findings suggest that sputum microstructure as quantified by muco-
inert nanoparticle diffusion may serve as a novel indicator and/or risk factor for COPD 
severity and progression. 
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There is currently no cure for COPD. Treatment options are limited to symptom 
relief and do not arrest or reverse the deterioration in lung function and architecture that 
accompanies the disease. Elevated transforming growth factor beta (TGF-) signaling is 
strongly implicated as a key contributor to COPD development and progression. We have 
previously shown that an orally administered angiotensin receptor blocker (ARB) 
protected against airspace damage in animal models of COPD via TGF- antagonism. 
Here I engineered an inhalable drug nanocrystal (NC) formulation based the ARB 
telmisartan (TEL; TEL-NC) for the localized treatment of COPD. The TEL-NC possess a 
bio-inert surface coating that promoted colloidal stability and minimized macrophage 
uptake, and thus, improved the local drug concentration following inhalation compared to 
both inhaled and orally administered free drug. I then investigated the efficacy of inhaled 
TEL-NC in two widely explored animal models relevant to COPD. Treatment with TEL-
NC provided a protective effect in an acute cigarette smoke (CS)-induced injury model 
via suppression of TGF- signaling and attenuation of oxidative stress and inflammation. 
In the tight-skin (TSK) transgenic emphysema model, inhaled TEL-NC provided 
therapeutic resolution of disease pathogenesis, while orally administered free drug had no 
therapeutic effect. These findings suggest that inhaled TEL-NC can prevent and/or 
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Chronic obstructive pulmonary disease (COPD) is currently the third leading cause 
of death in the United States with continuously elevating morbidity and mortality. COPD 
is a complex progressive disease primarily caused by cigarette smoke (CS) as well as 
other inhaled pollutants. The disease is characterized by chronic, irreversible obstruction 
of airflow from the lung, which is resulted from both airspace enlargement (i.e. 
emphysema), as well as airway inflammation, remodeling, and mucus hypersecretion 
(chronic bronchitis).  
 Mucus hypersecretion is a hallmark of COPD and contributes to the accelerated 
lung function decline, reduced quality of life, and mortality in COPD. While alterations 
in the bulk physicochemical properties of mucus have been investigated, microstructural 
characteristics of mucus that punctuate COPD disease progression have not yet been 
explored. In Chapter 3, I employed muco-inert nanoparticles to probe the sputum 
(expectorated mucus) from cigarette smokers without airway obstruction and patients 
with COPD. I investigated whether the mesh size of spontaneously expectorated sputum, 
as indicated by the muco-inert nanoparticle diffusion, correlated with impaired lung 
function and altered sputum composition. 
There is no cure for COPD and the current standard of care is limited to relieving 
symptoms relief and improving quality of life. Elevated transforming growth factor beta 
(TGF-) signaling is strongly implicated as a key contributor to COPD development and 
progression. We have previously shown that an orally administered angiotensin receptor 
blocker (ARB) protected against airspace damage in animal models of COPD via TGF- 
antagonism. In Chapter 4, I engineered an inhalable drug nanocrystal (NC) formulation 
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based the ARB telmisartan (TEL; TEL-NC) for the localized treatment of COPD. In 
Chapter 5, I then investigated the efficacy of the inhaled TEL-NC formulation in two 





2.1 Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary disease (COPD) is currently the third leading 
cause of death in the United States with continuously elevating morbidity and mortality 
[1]. Of the six leading causes of death in the U.S., it is the only one whose mortality is 
increasing [2]. Thus COPD poses a large burden and is a major public health concern. 
COPD is a complex progressive disease primarily caused by cigarette smoke (CS) as well 
as other inhaled pollutants [3]. The disease is characterized by chronic, irreversible 
obstruction of airflow from the lung, which is resulted from both airspace enlargement 
(i.e. emphysema), as well as airway inflammation, remodeling, and mucus hypersecretion 
(chronic bronchitis) [4]. The relative contributions of airspace destruction and airway 
disease vary from person to person adding a level of complexity to the disease.  
Common symptoms of COPD are dyspnea (i.e. breathlessness), chronic cough, 
and sputum production [4]. Spirometry is used to diagnose COPD and track lung function 
decline [5]. Specifically, airflow limitation (i.e. COPD) is defined as the ratio of the post-
bronchodilator forced expiratory volume in one second (FEV1) to the forced vital 
capacity (FVC) of 0.7 [4]. The FEV1 measurement indicates lung function and a decrease 
in FEV1 corresponds with lung function decline. Spirometry is a noninvasive and readily 
available test and is the most reproducible and objective measurement of airflow 
limitation [4]. The disease severity is classified based on the FEV1 percent predicted 
measured after inhalation of a short-acting bronchodilator and is classified into four 
stages by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) known as 
GOLD stages shown in Table 2.1 [4]. Results from surveys such as the modified British 
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Medical Research Council (mMRC) Questionnaire [6], the Chronic Respiratory 
Questionnaire [7], the St. George’s Respiratory Questionnaire (SGRQ) [8], and the 
COPD assessment test (CAT) also contribute to COPD symptom evaluation [4]. Since 
COPD is a heterogeneous disease that affects patients differently, a multidimensional 
assessment is necessary for diagnosis and assessment [9].  
There is currently no cure for COPD. Treatment options are limited to relieving 
symptoms, reducing frequency and severity of exacerbations, and improving quality of 
life. No therapies arrest or reverse the deterioration in lung function and architecture that 
accompanies the disease [10]. Smoking cessation influences the nature history of disease 
and is the most effective way to limit disease progression [11]. The primary 
pharmacological treatments for COPD are inhaled bronchodilators and corticosteroids [4, 
12]. Bronchodilators dilate the small airways which allows for increased airflow to the 
lungs and reduced dyspnea [13]. There are two main classes of bronchodilators, -
agonists and anti-muscarinics [13]. -agonists function by binding to -adrenergic 
receptors which stimulates smooth muscle relaxation, and there are both short-acting and 
long-acting -agonists (SABAs and LABAs, respectively) [4]. Anti-muscarinics prevent 
bronchoconstriction and mucus secretion via antagonism of muscarinic receptors. There 
are also short-and long-acting antimuscarinics (SAMAs and LAMAs, respectively) [4]. 
Often these medications are given in combination. Inhaled corticosteroids (ICS) are 
typically used in combination with LABAs in patients with severe COPD and 
exacerbations. Besides pharmacological therapy, oxygen therapy and exercise programs 




2.2 Airway mucus 
Airway mucus functions as a selectively permeable barrier, allowing nutrients, 
proteins, and other molecules to move through it, while protecting the underlying 
epithelium by excluding inhaled pathogens and particulates [15-17]. Once trapped, 
foreign materials are rapidly cleared from the lungs via mucociliary clearance (MCC) 
where the mucus is subsequently swallowed [16]. A mucus layer ~ 1-10 μm thick is 
maintained by continuous secretion of mucus from goblet cells present in the airways and 
submucosal glands [18] and lines the luminal surface of the lungs from the trachea to the 
terminal bronchioles.  
Airway mucus is a viscoelastic gel comprised of a complex mixture of mucins, 
cells, cellular debris, bacterial proteins, antibacterial products, and water [19]. The gel 
properties of mucus are produced mucins, which are large highly glycosylated proteins. 
The majority of the glycans on mucins are negatively charged imparting an overall 
negative charge to the mucin fibers. Mucins also contain cysteine rich domains where no 
glycosylation is present. These “naked” regions form into hydrophobic beads or globules 
that are stabilized by internal disulfide bonds  [16]. Thus mucus can adhesively trap 
particulates due to both electrostatic and hydrophobic interactions. Further, the gel 
structure formed by the mucin network sterically traps particulates that are larger than the 
mucus pore size.  
 
2.3 Mucus in COPD  
One cause of airflow obstruction in COPD is an accumulation of mucus in the 
airways.  This facet of COPD is referred to as chronic bronchitis (CB) and is typically 
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defined as the presence of a chronic, productive cough and sputum production for at least 
3 consecutive months in 2 consecutive years [20]. Sputum is mucus that is cleared via 
cough and expectorated from the mouth. Accumulation of mucus in COPD is due to both 
mucus overproduction and hypersecretion by goblet cells and submucosal glands [21, 22] 
as well as reduced clearance [23, 24], which results in luminal occlusion of airways [25]. 
The mucus hypersecretion in COPD has many causes including cigarette smoke exposure 
[26, 27], viral and bacterial infections [28, 29], and inflammation [29]. COPD patients 
with CB have an increased number of goblet cells and mucin stores [30]. Clinically, 
mucus hypersecretion and occlusion are associated with accelerated lung function decline 
[31], increased exacerbation and hospitalization rates [32], and increased mortality [33]. 
Many of the current treatments for COPD intervene in the physiological mechanisms of 
CB. For example, -agonists increase ciliary beat frequency while anti-muscarinics and 
gluococorticoids reduce mucus secretion and production, respectively [20].  
Alterations in the composition of mucus directly affect its biophysical properties, 
which can result in dysfunctional MCC and subsequent disease manifestations [34]. In 
COPD patients with CB, an enhanced expression of gel forming mucins and elevated 
overall sputum solids content is observed in the lumen of the small airways [21, 35]. The 
increased solids content in sputum samples from CB patients was found to correlate with 
elevated partial osmotic pressure of the mucus gel layer and impaired mucus clearance 
[36]. Furthermore, it was recently reported that the total mucin concentration was 
significantly higher in induced sputum from patients diagnosed with CB compared to 
those without CB [37]. Functional MCC is dependent on appropriate rheological 
properties of airway mucus [38]. Macro- (or bulk-) rheological measurements have 
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revealed an increased viscoelasticity of COPD sputum compared to mucus from healthy 
subjects [39], which is likely related to the elevated macromolecule concentration found 
in COPD sputum. 
 
2.4 Pulmonary drug delivery  
Inhalation drug delivery is a non-invasive strategy for the delivery of drugs 
systemically or locally to the lungs. In particular, inhalational delivery of drugs directly 
to diseased tissue in the lung is attractive as it provides direct, topical delivery of the drug 
on site in the lungs while negating first pass metabolism and reducing the exposure of 
other tissues to the therapeutic [40-44]. Unfortunately, drugs inhaled directly to the lung 
are rapidly removed via systemic absorption and mucociliary clearance [45, 46], resulting 
in a very short time that the drug concentration remains in the therapeutic window. 
Frequent daily administration and the short duration of clinical effects are major 
disadvantageous of inhaled drug formulations [47, 48]. Additionally, due to the extensive 
vascularization of the lungs, most inhaled drugs enter the systemic circulation within 
minutes of administration, which may lead to off-target effects.  
 
2.5 Nanoparticles for pulmonary drug delivery  
Pulmonary drug delivery via nanoparticles (NP) may address the shortcomings of 
conventional inhalational drug delivery by increasing the time the drug is in the 
therapeutic window and reducing systemic exposure directly following inhalation. Thus, 
this strategy can reduce the required dose, dosing frequency and systemic side effects. 
The advantages of locally administered nano-based systems can include, (i) sustained and 
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controlled release of drugs locally [49, 50], (ii) protection of cargo drugs against 
degradation or inactivation [51, 52], (iii) reduction of side effects by lowering total dose 
and dose frequency [53, 54], and (iv) potential to overcome a variety of extracellular and 
intracellular barriers due to nanometric size [55-59]. There are a variety of types carriers 
for lung delivery including nanoparticles, liposomes, dendrimers, and nanocrystals [47]. 
Specifically, biodegradable polymers are extensively used as the carrier to 
encapsulate therapeutics in nanoparticulates. Specifically, poly(lactic-co-glycolic acid) 
(PLGA), an FDA-approved material, is the most widely used biodegradable polymer for 
nanoparticulate drug delivery. PLGA is a versatile polymer and has been used to 
encapsulate a variety of small molecule drugs, proteins, and nucleic acids in particulate 
carriers [60]. In vivo, PLGA slowly bioerodes via hydrolysis of the ester backbone and 
breaks down into its monomeric components (lactic acid and glycolic acid) [61]. As these 
products are naturally occurring metabolites in the human body, PLGA is generally well 
tolerated in vivo for biomedical applications. 
 
2.6 Mucus penetrating particles 
Mucus is the primary barrier to effective pulmonary delivery of therapeutic 
nanoparticles. We have previously shown that densely coating NP surfaces with 
polyethylene glycol (PEG) produces muco-inert particles (MIP), also known as mucus-
penetrating particles (MPP),  that are capable of moving in various human mucus 
secretions without being trapped by adhesive interactions with the mucus [62-65]. PEG is 
a hydrophilic and neutrally charged polymer thus surface PEGylation negates the 
electrostatic and hydrophobic interactions with mucus. The diffusion of MIP in mucus 
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can be slowed by steric obstruction imposed by the microstructure of the gel. In other 
words, MIP of a given size will move more slowly in a mucus sample with a tighter 
mesh, especially if the MIP diameter approaches the average pore size of the mucus [62-
65]. Conversely, conventional polymeric NP are trapped in mucus regardless of particle 
size due to adhesive interactions with mucus constituents; such particles are referred to as 
“conventional particles” (CP) or muco-adhesive particles (MAP). Thus, NP must be both 
smaller than the mucus mesh spacing and possess a dense surface coating of PEG in 
order to effectively diffuse in mucus.  
The diffusion of variously sized MIP has previously been employed as a 
biophysical tool to probe the microstructure of human cervical vaginal [62], respiratory 
[64], and chronic rhinosinusitis mucus [65] and cystic fibrosis (CF) sputum [63, 66]. 
Multiple particle tracking (MPT) allows simultaneous tracking of hundreds of individual 
particles in highly complex and heterogeneous biological specimens at high 
spatiotemporal resolution and quantification of individual particle transport rates [67]. 
MPT is a powerful and versatile technique. Specifically, using this technology we have 
found that MIP as large as 200 nm are capable of rapidly diffusing in respiratory mucus 
collected from endotracheal tubes [64]. We also determined the average pore size of 
sputum from patients with CF to be ~140 ± 50 nm [63]. Further, we demonstrated that the 
addition of a mucolytic to CF sputum improved the diffusion of MIP indicating an 
increase in the microstructure [66, 68].  
This information can also be applied to design drug and gene carriers for inhaled 
delivery to potentially improve the efficacy of the therapeutic compared with 
conventional nanoparticles or free drug formulations [69]. Pulmonary delivery of various 
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types of MIP including polystyrene [70], biodegradable [70], and non-viral gene vectors 
[71, 72] exhibited improved distribution in mouse lung airways and airspace compared to 
their unPEGylated counterparts. Importantly, the MIP formulations were retained in the 
lungs longer than the MAP [70-72]. The improved distribution and retention translated to 
improved efficacy in an acute model of lung inflammation of dexamethasone phosphate 
loaded PLGA NP [70] and also enhanced transgene expression in the lungs [71, 72]. 
 
2.7 Drug Nanocrystals 
Drug nanocrystals (NC) or nanosuspenions (NS) have become a widely used 
strategy to address the limitations of poorly water soluble drugs [73, 74]. Drug NC are 
particulates that are less than 1 micron and consist solely of the drug and a surfactant for 
stabilization. The nanonization process increases the surface area to volume ratio which 
increases the solubility and dissolution rate thereby improving the drug bioavailability 
and pharmacokinetics [75]. The two primary methods used to produce NC are either 
bottom up where the drug is precipitated or top down where mechanical force such as 
media milling or homogenization physically breaks apart the large insoluble particulates 
[73, 74]. However, only the top down approaches are currently used in the production of 
commercial products [76]. Drug NC have many advantages including, high efficiency of 
drug loading, feasibility for scale up, and applicability to a variety of administration 
routes [74]. The simplicity of the composition and the well-established industrial practice 
also result in lower regulatory barriers for the development of NS products. There are 
currently multiple NC formulations approved for clinical use and many more in 
preclinical development [73, 77]. 
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We have previously developed a mucus penetrating NC formulation with curcumin 
(CUR) composed solely of the drug and Pluronic F127 [78]. Pluronics are triblock 
copolymer surfactants composed of hydrophobic polypropylene oxide (PPO) flanked by 
two hydrophilic polyethylene oxide (PEO, aka PEG) arm segments. The hydrophobic 
PPO core group can adsorb onto hydrophobic surface of nanoparticle surfaces, while the 
PEG chains form a hydrophilic and neutral shell that can shield the particle surface from 
interactions with mucus [79]. Of the multiple Pluronics tested, the F127-coated CUR NC 
exhibited the highest diffusions rates in cystic fibrosis sputum. Interestingly, the ability to 
penetrate mucus was dependent on the PPO molecular weight as opposed to the PEG 
molecular weight. In vivo, inhaled F127 CUR NC exhibited improved coverage of the 
airway epithelium compared with the non-mucus penetrating F68 CUR NC and free 
CUR.  
 
2.8 TGF- pathway and COPD  
The transforming growth factor (TGF)-β superfamily consists of over 40 members 
that act as multifunctional regulators of cell growth and differentiation during organ 
development [80, 81]. Three TGF-β isoforms, including TGF-β1, β2 and β3, have been 
identified in the mammalian lungs and play distinct roles in lung development and repair 
[82]. These TGF-β isoforms all bind to the type II TGF-β receptor and mediate the 
recruitment of the type I receptor to form a heteromeric complex, thereby initiating a 
stereotyped series of cell-type specific responses in the lung airways (i.e. bronchi and 
bronchioles) and airspace (i.e. alveoli) [82]. TGF-β signaling is tightly controlled to 
maintain physiological homeostasis in the healthy lung [82]. Alterations in TGF- 
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expression is associated with COPD development and progression, and elevated TGF- 
levels have been shown in both the airway and airspace compartments of patients with 
COPD [83]. Further, in pre-clinical models, cigarette smoke exposure increases TGF-β 
signaling throughout the lung parenchyma, thereby triggering oxidative stress injury, 
inflammation, epithelial cell death and airway remodeling [84-88]. These processes likely 
culminate in the small airway obstruction and airspace destruction that are hallmarks of 
COPD.  
 
2.9 COPD animal models 
There are a variety of COPD mouse models and these are typically classified as 
either acquired/induced or genetic models. The most commonly used induced models are 
generated by exposure to cigarette smoke (CS) [89-91]. This is logical given that the 
primary risk factor for COPD development and progression in humans is tobacco smoke. 
The COPD-like pathology is established by daily CS exposure for an extended period of 
time, typically weeks to months, either via whole body or nose-only exposure systems 
[90]. While nose-only systems allow for more direct control of the CS exposure 
compared with whole body exposure, they also require prolonged restraint of the animals. 
Further, the number of animals that can be exposed at a time is limited with the nose-only 
systems. Regardless of exposure modality, mice exposed to chronic CS develop airspace 
enlargement, small airway remodeling, chronic inflammation, and elevated oxidative 
stress [92].  However, the major limitation of smoke exposure models is that regardless of 
the model parameters, the pathology of severe disease in humans cannot be replicated 
[89]. Specifically, while CS exposure can produce the emphysema phenotype, mucus 
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hypersecretion and airway obstruction are not established despite the presence of goblet 
cell metaplasia and airway remodeling [92]. Thus, the typical CS exposure models may 
only be appropriate to evaluate therapeutics for emphysema as opposed to the chronic 
bronchitis phenotype. Additionally, there is little standardization of the CS-exposure 
model across labs [89, 91]. The mouse strain and type of cigarettes used can greatly 
impact the degree of disease produced.  
Another acquired model is generated by inhalation of neutrophil or pancreatic 
elastase can also be used to induce emphysema and inflammation [89]. A major 
advantage of this model is that emphysema can be rapidly induced by only a single 
administration of elastase, compared with the CS-exposure model that can take six 
months to establish [91]. However, the mechanisms behind elastase emphysema are 
unclear and may not be as relevant to CS generated emphysema.  
The COPD animal models based on genetic variations include natural mutant, 
transgenic and knockout models [93]. Compared with the acquired models of COPD, the 
genetic models offer consistency and assurance of disease development; however, they 
do not necessarily reflect the lung pathogenesis relevant to COPD in humans. 
Interestingly, there are several spontaneous mutants that manifest an emphysema 
phenotype [93]. One example is the tight skin (TSK) mouse which has a heterozygous 
mutation in fibrilin-1[94]. Fibrilin-1 is a glycoprotein that is involved extracellular matrix 
deposition during development and remodeling [95].  This mutation results in excess 
matrix deposition with fibrosis in the skin as well as impaired alveolar septation that 
evolves into progressive airspace enlargement [96, 97]. This phenotype is at least 
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partially attributed to cell death as a result of oxidative stress [98]. However, 

















I Mild <0.07 ≥80% of normal 
II Moderate <0.07 50-79% of normal 
III Severe <0.07 30-49% of normal 
IV Very severe <0.07 <30% of normal 
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3. Nanoparticle diffusion in spontaneously expectorated sputum as a 
biophysical tool to probe disease severity in COPD 
3.1 Introduction 
Mucus abnormalities contribute to chronic morbidity in a variety of lung diseases, 
including chronic obstructive pulmonary disease (COPD) [100, 101], cystic fibrosis (CF) 
[102], and asthma [103]. COPD is the third leading cause of death in the US [1], and at 
least 30% of people with COPD have chronic bronchitis (CB), characterized by chronic 
cough and sputum production [104, 105]. In healthy lungs, mucus that lines the luminal 
surface of lung airways serves a critical protective purpose by trapping inhaled 
particulates and pathogens that are subsequently cleared from the airways via mucociliary 
clearance (MCC) [17, 106]. However, in obstructive lung diseases, mucus hypersecretion 
can overwhelm mucus clearance mechanisms and result in bacterial overgrowth, chronic 
airway inflammation, and airway obstruction [107]. Specifically in COPD, mucus 
hypersecretion is associated with accelerated lung function decline [31], increased 
hospitalization rate, and increased mortality [32]. Mucus obstruction of the small airways 
may also be a significant predictive factor of COPD progression and mortality [25, 108], 
as well as exacerbation risk [109-111].  
Airway mucus is a viscoelastic gel comprised of a complex mixture of high 
molecular weight mucin glycoproteins, cells, cellular debris, bacterial proteins, 
antibacterial products, and other molecules [19]. Alterations in the composition of mucus 
directly affect its biophysical properties, which can result in dysfunctional MCC and 
subsequent disease manifestations [34]. In COPD patients with CB, an enhanced 
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expression of gel forming mucins and elevated overall sputum solids content is observed 
in the lumen of the small airways [21, 35]. Recently, Anderson and colleagues found that 
increased solids content in sputum samples from CB patients correlated with elevated 
partial osmotic pressure of the mucus gel layer and impaired mucus clearance [36]. 
Functional MCC is dependent on appropriate rheological properties of airway mucus 
[38]. Macro- (or bulk-) rheological measurements have revealed an increased 
viscoelasticity of COPD sputum compared to mucus from healthy subjects [39], which is 
likely related to the elevated macromolecule concentration found in COPD sputum. 
However, conventional bulk rheology measurements do not reveal properties of mucus or 
sputum at the microscopic level, which significantly contribute to mucus physiology and 
may correlate with disease pathology [112].  
The diffusion rate of variously sized nanoparticles has previously been employed 
as a biophysical tool to probe the microstructure of human mucus and sputum secretions 
[62-65], as well as other biological specimens, including the vitreous gel [113], brain 
extracellular matrix [114] and tumor tissues [115]. Compared to other methods such as 
fluorescence recovery after photobleaching (FRAP) that only provide ensemble-averaged 
diffusion rates, multiple particle tracking (MPT) allows simultaneous tracking of 
hundreds of individual particles in highly complex and heterogeneous biological 
specimens at high spatiotemporal resolution and quantification of individual particle 
transport rates [67]. We have previously shown that densely coating nanoparticle surfaces 
with polyethylene glycol (PEG) produces muco-inert nanoparticles (MIP), also known as 
mucus-penetrating particles (MPP),  that are capable of moving in various human mucus 
secretions without being trapped by adhesive interactions with the mucus [62-65]. The 
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diffusion of MIP in mucus can be slowed by steric obstruction imposed by the 
microstructure of the gel. In other words, MIP of a given size will move more slowly in a 
mucus sample with a tighter mesh, especially if the MIP diameter approaches the average 
pore size of the mucus [62-65]. Conversely, conventional polymeric nanoparticles are 
trapped in mucus regardless of particle size due to adhesive interactions with mucus 
constituents; such particles are referred to as “conventional particles” (CP) or muco-
adhesive particles (MAP). 
In this pilot study, we characterized MIP diffusion in spontaneously expectorated 
sputum from a cohort of cigarette smokers with and without airway obstruction to assess 
whether the sputum microstructure that governs MIP transport is associated with COPD 
disease severity and airway obstruction. Using MPT we found that sputum 
microstructure, as measured by MIP diffusion rates, correlated inversely with COPD 
disease severity and positively with FEV1/FVC ratio. A significant correlation was also 
observed between sputum microstructure and percent solids content and DNA 
concentration, respectively. Some of the results of these studies have been previously 
reported in the form of an abstract [116]. 
 
3.2 Methods 
3.2.1 Collection of spontaneously expectorated sputum 
Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a 
multi-center longitudinal, observational study to identify novel phenotypes and 
biomarkers of COPD [117]. Smokers (pack years ≥20 years) with or without airway 
obstruction were pre-stratified into three categories based on spirometric pulmonary 
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function measurements, specifically forced expiratory volume in 1 second (FEV1) and 
forced vital capacity (FVC): cigarette smokers without airway obstruction (smoker, 
FEV1/FVC>0.70, FVC>LLN), mild-moderate COPD (mCOPD, FEV1/FVC<0.70, 
FEV1>50%), and severe COPD (sCOPD, FEV1/FVC<0.70, FEV1<50%). For our study 
specifically, participants were asked to provide an expectorated sample if possible at the 
same time as one of their annual scheduled SPIROMICS visits before providing an 
induced sample. Participants rinsed their mouths with water and after a deep breath with 
slow exhalation used a coughing manoeuvre to produce a deep sputum sample. Samples 
were stored at 4°C and analyzed by MPT within 24 h of collection in order to minimize 
sample degradation [66]. Aliquots used to determine mucin and DNA content were 
frozen at -80°C until use.  
 
3.2.2 PEGylation of PS particles 
Fluorescent, carboxylate-modified polystyrene particles (PSCOOH) ranging in 
size from 100-500 nm were purchased from Life Technologies (Carlsbad, CA). PEG-
modified particles (PSPEG) ranging in size from 100-500 nm were prepared by 
covalently conjugating 5 kDa methoxy-PEG-amine (Creative PEGworks, Winston Salem, 
NC) to the carboxyl groups on PSCOOH using carbodiimide coupling chemistry, as 
previously described [114]. Particle hydrodynamic diameter, polydispersity index (PDI), 
and surface charge (-potential) were measured by dynamic light scattering (DLS) and 
laser Doppler anemometry with a Malvern Zetasizer Nano ZS (Malvern Instruments) in 




3.2.3 Multiple particle tracking 
MAP and MIP diffusion in sputum was measured by MPT, as previously 
described [67, 118]. Sputum aliquots (~30 l) were taken out of the sputum sample using 
a Wiretrol (Drummond Scientific Company, Broomall, PA) and placed in custom 
microscopy chambers. Diluted nanoparticle suspensions were added to the sputum at a 
final dilution of ~3% v/v. A 0.5 l aliquot of green fluorescent PSCOOH plus 0.5 l of 
red fluorescent PSPEG particles for each particle size (100, 200, and 500 nm) were added 
to each chamber. The samples were gently stirred and the chambers were sealed with a 
coverslip to prevent sample dehydration and equilibrated for 30 minutes before imaging. 
The chambers were imaged at room temperature using an inverted epifluorescence 
microscope (Axio Observer; Zeiss, Germany) on a vibration table with a 100x/1.46 NA 
oil-immersion objective. Movies were recorded for 20 s at a temporal resolution of 67 ms 
using an EM-CCD camera (Evolve 512; Photometrics, Tuscan, AZ). 
Movies were analyzed with a custom automated particle tracking software in 
MATLAB (Mathworks; Natick, MA) to extract the x and y positions of particle centroids 
over time [67, 119]. At least 100 particles of each size and type were tracked for a 
minimum of 50 frames. The time-averaged mean squared displacement (MSD) as a 
function of time scale, , was calculated for each particle trajectory as: 
 〈∆𝑟2(𝜏)〉 =  〈[𝑥(𝑡 + 𝜏) − 𝑥(𝑡)]2〉 + 〈[𝑦(𝑡 + 𝜏) − 𝑦(𝑡)]2〉 
Sputum samples were assumed to be locally isotropic (although not homogenous), thus 
the 2D MSD measured can be extrapolated to 3D MSD [120]. Median MSD values were 
reported for each sample instead of the ensemble average due to the inherent 
heterogeneity, and non-normal distribution of muco-inert nanoparticle (MIP) diffusion in 
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COPD sputum [121]. Previously we showed that the estimated static error is much 
smaller than the particle displacements, therefore static error is not expected to 
significantly impact the calculated MSD [122]. Additionally, we previously found that 
the effect of static and dynamic error in MPT experiments was minimized for MSD 
measured at = 1 s (MSD1s). Thus, median log10MSD1s was used as our primary 
measurement readout [67, 119, 122].  
 
3.2.4 Quantification of sputum components 
The total solids content of sputum was determined by freeze-drying. Sputum sample 
aliquots of known mass were frozen in liquid N2 and lyophilized (Labconco, Kansas City, 
MO) for at least 12 hours to remove water from the samples. The sputum solid content is 
calculated as the ratio of dry mass to wet mass.  
 Mucin concentration was determined based on the reaction of 2-cyanoacetamide 
(Sigma-Aldrich) with O-linked glycoproteins, as previously described [123, 124]. 
Sputum aliquots were diluted 20-fold and homogenized by vortexing for at least 15 
minutes. Then, 50 l of the suspension was reacted with 60 l of an alkaline solution of 
2-cyanoacetamide (200 l of 0.6 M 2-cyanoacetamide mixed with 1 ml of 0.15 M NaOH) 
at 100ºC for 30 min. After incubation, 0.5 ml of 0.6 M borate buffer, pH 8.0, was added 
and the fluorescence intensity was measured at excitation and emission wavelengths of 
336 and 383 nm, respectively. Sputum mucin concentrations were calculated with 
reference to a standard curve generated using known concentrations of mucin from 
bovine submaxillary gland (Sigma-Aldrich). 
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 DNA concentration was measured using a fluorimetric assay based on the 
reaction of diaminobenzoic acid (DABA; Sigma-Aldrich) with DNA, as previously 
described [123]. Sputum aliquots were diluted 5-fold and homogenized by vortexing for 
at least 15 min. Next, 30 l of this suspension was mixed with 30 l of 20% w/v DABA 
solution and incubated at 60°C for 1 h. One ml of 1.76 M HCl was then added to stop the 
reaction. The fluorescence was measured at excitation and emission wavelengths of 390 
and 530 nm, respectively. Sputum DNA concentrations were calculated based on a 
standard curve generated using known concentrations of DNA from salmon testes 
(Sigma-Aldrich).  
 
3.2.5 Statistics  
Statistical significance was determined via a two-tailed Student’s t test, assuming 
unequal variances. Comparisons between multiple groups were determined using one-
way analysis of variance (ANOVA) with Tukey’s post hoc test. Calculations were 








3.3.1 Participant characteristics 
Demographic data was available on 36 participants: 9 smokers, 19 with mild-
moderate COPD (mCOPD), and 8 with moderate-severe COPD (sCOPD) (Table 3.1). 
The transport analysis based on particle surface property and nanoparticle size was 
performed on samples from 18 participants (5 smokers, 7 mCOPD, 6 sCOPD) (Table 
3.2). An additional 18 samples (4 smokers, 12 mCOPD, 2 sCOPD) were collected for the 
microstructure correlations between the biochemical composition and the lung function 
parameters; however, not all data was available for all patients.  
 
3.3.2 Transport of nanoparticles in spontaneously expectorated sputum from smokers 
without airway obstruction 
Nanoparticle movement in mucus approximates both the mesh “tightness” and the 
pore size within the mucus gel [66]. To establish whether differences in particle diameter 
and mucus adhesivity affected particle movement in sputum from smokers, we first 
compared the transport behavior of MIP to that of similar sized MAP in spontaneously 
expectorated sputum samples from cigarette smokers without airway obstruction (n = 5). 
The dense PEG coating on the MIP resulted in an increased particle diameter and more 
neutral surface charge as measured by the-potential (Table 3.3). For simplicity, 
hereafter we refer to nanoparticles based on their nominal size as reported in Table 3.3. 
We found that MAP, regardless of particle diameter, did not move rapidly through the 
sputum samples, as evidenced by their highly confined trajectories (Figure 3.1A, top). In 
contrast, 100 nm MIP moved through the sputum samples readily (Movie E1), as 
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evidenced by their diffusive trajectories (Figure 3.1A, bottom). We further quantified 
diffusion rates of each particle type, as parameterized by the median MSD. MSD 
represents the distance traveled by an individual particle in a given time interval (i.e. time 
scale) and, thus, MSD linearly correlates with particle diffusion rates.  Although we 
observed that 300 nm MIP appeared to move more freely in sputum than 300 nm MAP, 
only the 100 nm particles displayed a statistically significant difference in MSD between 
the MIP and MAP at a time scale of 1 s (Figure 3.1B; p < 0.05). Further, both the 500 nm 
MIP and MAP moved exceedingly slowly in sputum, and the difference in MSD between 
500 nm MIP and MAP was not significant.   
 
3.3.3 Transport of nanoparticles in spontaneously expectorated sputum from patients 
with COPD  
We next compared the diffusion of MAP and MIP in sputum samples collected 
from patients with COPD (n = 13; Movie E2, 100 nm MIP). The 100 and 300 nm MIP 
exhibited more diffusive trajectories as compared to those of similar sized MAP (Figure 
3.2A). Quantitatively, the MSD of 100 and 300 nm MIP were significantly greater than 
that of the MAP counterparts (Figure 3.2B, p<0.05). Similar to the observation in smoker 
sputum, 500 nm MIP and MAP were both trapped in COPD sputum: 500 nm MIP were 
trapped because they are too large to move through the pores (Movie E3); 500 nm MAP 





3.3.4 Transport of MIP in sputum samples from smokers without airway obstruction, 
with mild-moderate COPD, and with severe COPD 
Diffusion of individual 100 and 300 nm MIP in smoker sputum samples exhibited 
unimodally higher diffusion rates compared with mCOPD and sCOPD samples, as 
quantified by particle log10[MSD1s] (Figure 3.3A and 3.3B, top panel). In contrast, 
particle transport was more obstructed in mCOPD and sCOPD sputum samples, as 
evidenced by the leftward shift of the MSD distribution and the reduced fraction of 
rapidly diffusing nanoparticles (Figure 3.3A and 3.3B, middle and bottom panels). In 
particular, the distribution of individual particle log10[MSD1s] in sCOPD was multi-
modal with a larger fraction of slow-moving particles (Figure 3.3A and 3.3B, bottom 
panel). Specifically, this trend was most pronounced when comparing the 100 nm MSD 
in the extreme conditions of smoker versus sCOPD. Similarly, there was a decreasing 
trend of rapidly moving particle populations with respect to disease severity with the 300 
nm MIP. The MSD distribution of 500 nm MIP in sputum was similar regardless of 
disease severity, with the majority of the particles exhibiting low MSD values, suggesting 
that 500 nm MIP are significantly larger than the sputum average pore size (Figure 3.3C). 
Based on these results, subsequent studies were solely assessed against transport of 100 
nm MIP. 
 
3.3.5 Sputum biochemical composition analysis 
We hypothesized that the biochemical composition might impact the 
microstructural properties of sputum and, thus, we measured the macromolecular 
contents of the sputum samples. The percent solids in the sputum collected ranged from 
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1.1–6.5% by weight, with the higher values primarily associated with more severe 
disease. The solids content for samples from smokers and COPD patients was 2.4 ± 1.0% 
and 3.2 ± 1.2% on average, respectively, which is in agreement with previously published 
values [35]. Sputum from sCOPD patients exhibited the highest percent solids content 
(3.5 ± 0.7%), while the percent solids for smoker and mCOPD samples were 2.4 ± 1.0% 
and 3.1 ± 1.4%, respectively (Figure 3.4A). The solids content in the sCOPD group was 
significantly higher than that in the smoker group (p < 0.05). We then compared the 
percent solids content values with the corresponding 100 nm MIP median log10[MSD1s], 
and found that the median log10[MSD1s] inversely correlated with percent solids (Figure 
3.5A; r = -0.62, p<0.0001). 
We next measured concentrations of the primary macromolecules found in 
sputum, specifically mucin and DNA, and investigated whether there is a relationship 
between their concentrations and the diffusion rates of 100 nm MIP. The mucin 
concentration was about 2-fold higher in the amassed COPD sputum samples compared 
to that from smokers (5.34 ± 3.6 and 2.8 ± 1.1 mg/ml, respectively). Specifically, the 
severe COPD cohort possessed the highest sputum mucin concentration at 7.9 ± 4.9 
mg/ml and was statistically significant compared with that of both the smokers and the 
mild COPD group (4.1 ± 1.8 mg/ml), respectively (Figure 3.4B, p<0.01). The DNA 
concentration was higher in COPD sputum compared to smoker sputum, averaging 0.24 
± 0.38 and 0.08 ± 0.06 mg/ml, respectively (Figure 3.4C), but it was not statistically 
significant in this small cohort of patients. When related to nanoparticle diffusion, mucin 
concentration inversely correlated with the median log10[MSD1s] of 100 nm MIP (Figure 
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3.5B; r = -0.62, p=0.0009); however, the relationship was not statistically significant for 
DNA content and median log10[MSD1s] of 100 nm MIP (Figure 3.5C; r = -0.22, p=0.23).  
 
3.3.6 Relationship between lung function and microstructure   
We hypothesized that the altered sputum microstructure in COPD may correlate 
with impaired lung function. The median log10[MSD1s] of 100 nm MIP was positively 
correlated with the spirometric measurements of FEV1/FVC (Figure 3.6A; r = 0.39, 
p=0.03) and FEV1% predicted (Figure 3.6B; r = 0.45, p=0.02). We also compared the 
spiromic measurements to the solids content which has been shown to be a possible 
biomarker for lung function [35]. Neither the FEV1/FVC nor the FEV1% predicted 
significantly correlated with the sputum percent solids (Figure 3.6C).  
 
3.3.7 Statistics 
Statistical significance was determined via a two-tailed Student’s t test, assuming 
unequal variances. Comparisons between multiple groups were determined using one-
way analysis of variance (ANOVA) followed by a Tukey post hoc test. Pearson 
correlation analysis was used to determine r values. Calculations were performed using 






In this preliminary study, we examined whether sputum architecture, reflecting 
gel pore size, associates with COPD severity and sputum composition. To our 
knowledge, this is the first analysis of sputum microstructure in COPD patients. We 
specifically investigated the microstructural properties of spontaneously expectorated 
sputum from smokers with and without airway obstruction using MPT with muco-inert 
probes. We showed that dense surface coatings with low molecular weight PEG 
effectively prevented nanoparticle adhesion to sputum constituents for particles smaller 
than the mesh spacing, similar to our observations with other mucus secretions, including 
cervicovaginal mucus [62], respiratory mucus [64], chronic rhinosinusitis mucus [65], 
and CF sputum [63]. We also demonstrated that the diffusion rates of MIP possessing 
particle diameter less than the average sputum mesh size (100 nm MIP in this case) can 
be used to distinguish potentially key biophysical properties of sputum collected from 
patients with varying disease severity. Using our microstructure measurement we found 
that a tightened microstructure correlated with lung disease severity as indicated by a 
decrease in in FEV1/FVC and FEV1. In addition, patient-specific analysis of sputum 
microstructure may aid in the development of personalized treatments for effective 
inhaled therapy. Finally, although not determined here, the mesh spacing (a direct 
measurement of pore size) of the sputum network may impact the migration of 
microorganisms [125, 126], including bacteria and immune cells. If so, the mesh spacing 
measurement can potentially serve as a predictive index of COPD-associated 
exacerbation, a critical risk factor for COPD [127].  
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Sputum is a gel that is composed of a complex porous network of solid strands of 
mucins, DNA and other molecules in an aqueous medium. In order to accurately perform 
microstructural analysis of the sputum mesh via MPT, the nanoparticle probes must be 
both non-adhesive and smaller than the average pore size in the sputum mesh [112]. 
Transport rates of MAP are strongly affected by adhesive interactions with the sputum, 
whereas MIP resist adhesive interactions with sputum constituents. Due to their muco-
inert nature, MIP movement is primarily affected by steric obstruction imposed by the 
sputum mesh, which makes MIP uniquely appropriate for use in examination of sputum 
architecture, such as mesh spacing. We found that 100 nm MIP traveled with relatively 
little resistance through the porous sputum gel samples obtained from both smokers and 
COPD patients. In contrast, 500 nm MIP, despite their muco-inert surfaces, did not 
diffuse rapidly in sputum because they are too large to fit through the sputum pores. 
These findings indicate that 100 nm MIP are optimal to probe the sputum microstructure, 
whereas conventional mucoadhesive particles (MAP) and MIP larger than the average 
opening size in the sputum mesh are not suitable for this application.   
Biophysical properties of COPD sputum have been relatively underexplored 
compared to biochemical content analysis, including quantification of pro-inflammatory 
and bacterial cell markers [128, 129]. Previous biophysical analysis of sputum samples 
collected from patients with obstructive lung diseases primarily focused on measurement 
and comparison of macro-rheological properties; for example, the degree of purulence, an 
indication of infection, in CF sputum samples positively correlated with the bulk 
viscoelasticity [39]. However, these conventional rheological measurements, while 
beneficial for understanding macroscopic behavior of the biological fluid, do not provide 
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direct information on sputum microarchitecture [67, 130]. By combining MIP and the 
MPT technique to probe sputum microstructure, we discovered a significant correlation 
between diffusion of 100 nm MIP and disease stage, specifically between sputum 
samples from smokers and sCOPD patients. The reduction in MIP diffusion rates, as 
quantified by median log10[MSD1s], as well as the decrease in the fraction of fast-moving 
MIP in sCOPD sputum, indicates that the sputum mesh, i.e. pore size, is tighter in severe 
COPD.  
Consistent with previous reports [35, 36], we found a modest increase in the 
percent solids content of sputum samples from COPD patients compared with that of 
smokers. The elevation was particularly evident in the severe COPD population. We 
found a significant inverse correlation between percent solids and the MIP median 
log10[MSD1s], suggesting that a greater solids concentration, as can occur with sputum 
dehydration [36] or mucin hypersecretion, contributes to a tighter sputum mesh in severe 
COPD. This is in agreement with a previous finding where in vitro particle diffusion rates 
in mucus inversely correlated with solids content [35]. However, it should be noted that 
this study was conducted with large (1 m), non-PEGylated (muco-adhesive) particles 
and, thus, the diffusion readout is more relevant to bulk rheological mucus properties 
than to microstructural properties such as pore size [131].   
 Many believe that airway inflammation in obstructive lung disease is linked to 
perturbation of mucin [132] and/or DNA content [133], which results in elevation of 
mucus elasticity [106, 134]. We found that the mucin concentration was significantly 
increased in   in sputum samples collected from COPD patients compared with those 
from smokers. This is in agreement with a recently published paper from the 
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SPIROMICS study that found that the total mucin concentration was significantly higher 
in induced sputum from patients diagnosed with CB compared to those without CB [37]. 
Further, the mucin concentration corresponded with a tighter sputum microstructure. 
Additionally the pore size of the mucus mesh can also be affected by the crosslinking 
density of mucin fibers [134, 135]. Yuan and coworkers have recently reported that 
oxidation arising from airway inflammation increases the amount of disulfide crosslinks 
of mucin polymers and, thus, increases the stiffness/elasticity of CF sputum [134]. 
Increased oxidative stress is also a hallmark of COPD-associated lung disease [136, 137].  
 We found that sputum microstructural properties correlated with lung function 
measures (i.e. FEV1/FVC and FEV1 % predicted). In CF sputum, altered sputum 
rheological properties correlate with bacterial colonization and reduced lung function 
[138]. The tighter mesh in COPD sputum may also provide a permissive environment for 
chronic infection and inflammation, perhaps due to reduced bacteria and neutrophil 
migration coupled with reduced MCC [125]. Thus, microstructure readouts based on MIP 
diffusion in sputum may find use in the study of disease progression and/or clinical 
exacerbations. Importantly, there is not a significant relationship between lung function 
and percent solids thus limiting the solids content as a biomarker for lung disease 
severity. In particular, MPT analysis with 100 nm MIP appears appropriate for 
prospective clinical trials and epidemiology studies focused on the modification of 
sputum properties. Biophysical analysis of COPD sputum by MPT with 100 nm MIP may 
potentially be used in the future to tailor therapy and to evaluate effectiveness of 
therapeutics, including mucolytic agents [139]. Finally, our findings invite further 
analysis of the molecular interactions that contribute to pore size such as disulfide cross-
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linking, oxidative modifications and mucin-macromolecule interactions. The 
approximation of pore size also provides critical measurements for in vitro modeling of 
the mucus gel structure in various disease states.    
Of note, the microstructure measurement can only be performed on fresh, 
spontaneously expectorated sputum in order to preserve the physiological structure and to 
prevent deterioration observed with prolonged storage or freezing [66]. Induced sputum 
samples were not used as dilution by inhaled saline during the collection process may 
alter the physiological microstructure. Thus, the COPD patient population sampled with 
this method is constrained by the ability to generate a spontaneous specimen.  
 
3.5 Conclusion 
Overall, our findings suggest that the characterization of sputum microstructure, 
available with spontaneous but not induced sputum samples, may provide novel insights 
into the specific properties of mucus that contribute to COPD pathogenesis. Future 
studies will focus on the examination of sputum architecture in larger longitudinal 
cohorts with detailed clinical, physiologic and functional readouts. Such studies could 





Figure 3.1. Transport of muco-adhesive and muco-inert polystyrene 
nanoparticles in spontaneously expectorated sputum from cigarette 
smokers without airway obstruction. (A) Representative trajectories of 
polystyrene nanoparticles possessing nominal sizes of 100, 300, and 500 with 
(MPP) or without (MAP) the muco-inert PEG surface coating. Trajectories 
show 3 s of motion. (B-D) Median mean squared displacement (MSD) at a 
time scale of 1 s for particles with nominal sizes of (B) 100 nm, (C) 300 nm, 
and (D) 500 nm MAP and MIP. Data represents n=5 sputum samples with at 
least 500 particles tracked per sample. Error bars represent standard error of 
the mean. *Denotes statistically significant differences (p < 0.05) 
A 




Figure 3.2. Transport of muco-adhesive and muco-inert polystyrene 
nanoparticles in spontaneously expectorated sputum from COPD patients. 
(A) Representative trajectories of polystyrene nanoparticles possessing nominal 
sizes of 100, 300, and 500 nm with (MIP) or without (MAP) the muco-inert PEG 
surface. Trajectories show 3 s of motion. (B-D) Median mean squared 
displacement (MSD) at a time scale of 1 s for particles with nominal sizes of (B) 
100 nm, (C) 300 nm, and (D) 500 nm MAP and MIP. Data represents n=13 
sputum samples with at least 500 particles tracked per sample. Error bars 
represent standard error of the mean. *Denotes statistically significant differences 
(p < 0.05) 
A 






Figure 3.3. Diffusion of different sized muco-inert nanoparticles in 
spontaneously expectorated sputum from patients stratified for COPD 
severity based on spirometric pulmonary function measurements: cigarette 
smokers without airway obstruction (Smoker, n=5), mild COPD (mCOPD, n=7), 
severe COPD (sCOPD, n=6). Distribution of the log10[MSD1s] of individual MIP 
with nominal sizes of: (A) 100 nm, (B) 300 nm, and (C) 500 nm. Data represents 
at least 500 particles tracked per sample. The average median log10[MSD1s] for 
each set is indicated by the dashed line.  
A                 B                    C  





Figure 3.4. Sputum biochemical contents. Quantification of (A) percent solids 
(B) mucin concentration and (C) DNA concentration in sputum from smokers 
without airway obstruction (Smoker), mild COPD (mCOPD) and severe COPD 
(sCOPD). Error bars represent the standard error of the mean for each data set. 
*Denotes statistically significant differences (p < 0.05) 





Figure 3.5. Relationship between sputum microstructure and biochemical 
components. Transport of 100 nm MIP (median log10[MSD1s]) inversely correlates 
with (A) percent solids content (r = -0.61, p < 0.001) and (B) mucin concentration  
(r = -0.57, p < 0.001). (C) The median log10[MSD1s] does not correlate with  DNA 
concentration (r = -0.23, p = 0.2). 






Figure 3.6. Relationship between sputum microstructure and spirometric 
measurements. Transport of 100 nm MIP (median log10[MSD1s]) positively 
correlates with (A) the ratio of post-bronchodilator FEV1 to FVC ratio (r = 0.39, 
p < 0.05) and (B) post-bronchodilator FEV1 % predicted (r = 0.48, p < 0.05). (C) 
The percent solids and FEV1 % predicted are not correlated (r = -0.19, p = 0.34). 
Spirometry was performed on patients prior to sputum collection.  




















N 9 19 8 
Age 56.4 (6.78) 64.8 (9.87) 71.6 (7.96) 
    
Post-BD FEV1 % predicted 86.30 (17.9) 63.71 (13.9) 41.01 (7.9) 
FEV1/FVC 0.74 (0.07) 0.56 (0.08) 0.38 (0.06) 
    
Female, n (%) 5 (56%) 9 (47%) 3 (38%) 
Current smoker, n (%) 5 (56%) 11 (58%) 4 (50%) 
Table 3.1. Participant demographics 
LLN: lower limit of normal.  
Post-BD: post bronchodilator 





















N 5 7 6 
Age 53.4 (7.09) 59.17 (6.46) 66.17 (11.65) 
Pack-years 46.7 (17.59) 55.38 (19.18) 60.58 (21.90) 
    
Total exacerbations 1 (1.22) 0.67 (0.82) 0.5 (0.84) 
Post-BD FEV1 % predicted 87.18 (8.47) 59.03 (8.96) 38.32 (3.41) 
Post-BD FVC % predicted 96.1 (12.82) 80.75 (6.36) 81.3 (17.80) 
FEV1/FVC 0.73 (0.06) 0.59 (0.07) 0.38 (0.06) 
    
African American, n (%) 3 (60%) 2 (29%) 1 (17%) 
Female, n (%) 3 (60%) 3 (43%) 1 (17%) 
Current smoker, n (%) 4 (80%) 5 (71%) 5 (83%) 
Usual cough, n (%) 4 (80%) 3 (43%) 5 (83%) 
Usual phlegm, n (%) 3 (60%) 3 (43%) 4 (67%) 
Table 3.2. Participant demographics for microstructural analysis 
LLN: lower limit of normal.  
Post-BD: post bronchodilator 












100  PSCOOH 88 ± 1 0.02 -52 ± 1 
100  PSPEG 109 ± 2 0.02 -7 ± 1 
300  PSCOOH 292 ± 4 0.01 -75 ± 6 
300  PSPEG 318 ± 7 0.04 -4 ±1 
500  PSCOOH 538 ± 11 0.05 -52 ± 1 
500  PSPEG 553 ± 5 0.05 -4 ± 1 
a Hydrodynamic diameter and PDI measured by dynamic light scattering. 




4. Formulation of telmisartan nanoparticles for the local treatment of 
COPD 
4.1 Introduction  
Transforming growth factor (TGF)-β is a multifunctional regulator of cell growth 
and differentiation during organ development and plays a critical role in lung 
development and repair [80, 81]. TGF-β and the signaling is tightly controlled to 
maintain physiological homeostasis in the healthy lung [82]. Alterations in TGF- β 
expression is associated with COPD development and progression, and elevated TGF- β 
levels have been shown in both the airway and airspace compartments of patients with 
COPD. Further, in pre-clinical models, cigarette smoke exposure increases TGF-β 
signaling throughout the lung parenchyma, thereby triggering oxidative stress injury, 
inflammation, epithelial cell death and airway remodeling [84-88]. These processes likely 
culminate in the small airway obstruction and airspace destruction that are hallmarks of 
COPD. Thus, TGF- β signaling is an especially attractive candidate pathway that can be 
targeted for COPD treatment.  
Therapeutic interventions that antagonize TGF-β signaling may halt progression 
and/or reverse the pathogenesis of COPD. Angiotensin receptor blockers (ARB), specific 
antagonists of the angiotensin II type 1 receptor (AT1R), are antihypertensive agents 
widely utilized in the clinic. AT1R is expressed on the surface of airway and alveolar 
epithelial cells as well as lung vasculature [140, 141]. Importantly, ARB suppress de 
novo TGF-β expression [142-144] as well as extracellular activation of latent TGF-β 
[142-146] via AT1R antagonism. Previously, we demonstrated that daily oral 
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administration of an ARB, losartan (LOS), inhibited TGF- β signaling, and effectively 
protected against damage in the lungs of a chronic CS-exposed mouse model of COPD 
[85]. However, the high drug dose and frequent administration of the drug concentration 
required for TGF-β antagonism may result in adverse systemic side effects, which is 
especially important in elderly populations. 
Inhalation is a non-invasive route for the delivery of drugs locally to the lungs. 
Inhaled delivery provides direct, topical delivery of the drug to the site of disease while 
negating first pass metabolism and reducing systemic exposure of the therapeutic [40-43]. 
Unfortunately, inhalation of free drugs can be rapidly removed via systemic absorption 
and mucociliary clearance [45, 46], reducing the time that the drug concentration remains 
in the therapeutic window. Encapsulation in nanoparticles can address the limitations of 
conventional pulmonary delivery by improving lung drug levels over time and allow for 
reduced dose and/or dosing frequency. Thus we sought to engineer a nano-based ARB 
formulation for pulmonary delivery. In this study we used the ARB telmisartan (TEL) 
instead of LOS due to its readily active nature unlike LOS that requires hepatic activation 
[147, 148] and its intrinsically higher affinity to AT1R than LOS [149]. 
Previously we have established the design criteria for inhaled NP, specifically that 
the particles must be smaller than the respiratory mucus pore size, densely coated with 
poly(ethylene glycol) (PEG) to minimize interactions with the mucus, and stable in 
physiological conditions [70, 78]. We first attempted to encapsulate TEL in NP 
composed of the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA); however, 
due to challenges with effectively loading TEL in PLGA we instead engineered a 




4.2.1 Formulation of biodegradable TEL NP - Emulsion method  
Nanoparticles were prepared by a single emulsion method. Briefly, polymer (40 
mg, 75 mg/ml) and TEL (4 mg) were dissolved in dichloromethane (DCM) and sonicated 
in an aqueous phase of 5 ml of 0.5 % (w/v) emulsifier at 30% amplitude for 2 ml Vibra-
CellTM VCX-500 probe sonicator. The emulsion was then poured into 35 ml of 0.5% 
emulsifier under magnetic stirring (700 rpm) for 3 hours to evaporate the organic solvent. 
The nanoparticle suspension was filtered with a 1 um filter to remove aggregates before 
collection via centrifugation at 10,000g for 30 min. Nanoparticles were thoroughly 
washed and suspended in water. Various polymers and polymer combinations were 
tested, specifically PLGA45k-PEG5k (PLGA-PEG), a blend of PLGA2A and PLGA15k-
PEG5k (PLGA/PLGA-PEG), PLA45k-PEG5k, (PLA-PEG) and a blend of PLA and 
PLA45k-PEG5k (PLA/PLA-PEG). The emulsifiers tested were sodium cholate (CHA) and 
saponin.  
 
4.2.2 Formulation of biodegradable TEL NP - Zinc chelation method 
PLGA15k-PEG5k (15 mg), PLGA1A (10 mg), and TEL (2.5 mg) were dissolved 
in THF. ZnCl dissolved in THF was added to the polymer drug solution at various 
concentrations and incubated for 1 hour at room temperature. The THF solution was 
slowly added dropwise using a syringe into 30 ml of 5% F127 under magnetic stirring 
(700 rpm) for 2 hours to evaporate organic solvent. Subsequently, 0.5 ml of 0.5 M 
ethylenediaminetetraacetic acid (EDTA) was added to the nanoparticles to chelate excess 
zinc and remove free drug. The NP suspension was filtered with a 1 um filter to remove 
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aggregates before collection via centrifugation at 10,000g for 30 min. NP were 
thoroughly washed and resuspended in water. 
 
4.2.3 Characterization of TEL NP 
NP diameter and -potential were measured via dynamic light scattering (DLS) 
and laser Doppler anemometry, respectively, using a Zetasizer Nano ZS (Malvern 
Instruments) in 10 mM NaCl at pH 7.4 
 
4.2.4 TEL drug loading in biodegradable NP  
To measure the telmisartan content in the nanoparticles, a known amount of NP 
was frozen in liquid nitrogen, lyophilized, weighed and dissolved in a 50/50 mixture of 
methanol and 10 mM ammonium acetate. For the zinc chelation NP, 0.2 ml of 0.5 M 
EDTA was added and incubated for 30 min first. The TEL concentration was measured 
via reverse-phase high-performance liquid chromatography (HPLC). The mobile phase 
was composed of methanol and 10 mM ammonium acetate (35:65 v/v) containing 0.1% 
trifluoroacetic acid at a flow rate of 1 ml/min. Column effluent was monitored by UV 
detection at 240 nm. The drug loading was calculated based on the following equation:  





4.2.5 Formulation of TEL-NC 
TEL and Pluronic F127 or  Pluronic F68 (abbreviated as F127 and F68 hereafter, 
respectively) were dissolved in 2 ml of chloroform at a 1:4 mass ratio. The chloroform 
was rapidly evaporated with a nitrogen gas stream to create a film. The film was further 
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dried via vacuum overnight. The film was hydrated with ultrapure water and incubated 
for 20 minutes at room temperature followed by bath sonication for 10 minutes. The 
suspension was further homogenized with a Vibra-CellTM VCX-500 probe sonicator for 
30 minutes with a pulse of 1 second on 1 second off at 100% amplitude. The resultant 
suspension was centrifuged at 2000 rpm for 5 minutes to remove any large particulates. 
The TEL-NC were collected via centrifugation at 21130xg for 10 minutes and were 
resuspended in ultrapure water. TEL was dissolved in methanol and the drug 
concentration was measured using a spectrofluorophotometer (Shimadzu) at excitation 
300 nm and emission 360 nm with a slit width of 3 for both the excitation and emission. 
The TEL free drug (TEL-FD) was prepared by crushing Micardis® tablets into a powder 
and creating a suspension in water or fully dissolving the powder in 10% DMSO-water 
(v/v). 
 
4.2.6 Characterization of TEL-NC 
Transmission electron microscopy (TEM) was performed to visualize the drug 
formulations. F127/TEL-NC, F68/TEL-NC, or TEL-FD were diluted in water and 10 l 
of each formulation was added to copper TEM grids and incubated for 15 minutes. The 
remaining droplet was removed via wicking with filter paper. The grids were allowed to 
dry overnight and were subsequently imaged on a Hitachi H7600 microscope at 30k 
magnification. The dimensions of the F127/TEL-NC and F68/TEL-NC were measured 
with ImageJ software. F127/TEL-NC, F68/TEL-NC, or TEL-FD) were diluted in 
ultrapure water and the hydrodynamic diameter was measured via dynamic light 
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scattering (DLS) with a Zetasizer Nano ZS (Malvern). The zetapotential was measured 
vial laser Doppler anemometry in 10mM NaCl at pH 7.4 with a Zetasizer NanoZS.  
 
4.2.7 Animals  
All animal protocols were approved by the Institutional Animal Care and Use 
Committee at the Johns Hopkins Medical Institutions. Female CF-1 mice or male Wistar 
rats (6-8 weeks, Harlan) were allowed to acclimate for 1-2 weeks before handling, with 
access to food and water ad libitum throughout the experiments. 
 
4.2.8 Stability of TEL-NC in bronchial alveolar lavage fluid (BALF) 
Bronchial alveolar lavage fluid (BALF) was collected by sequentially lavaging 
mouse lungs three times with 1 ml of PBS. The cells were separated by centrifugation 
and discarded. The supernatant was collected and syringe filtered (0.2 mm). Twenty 
microliters of F127/TEL-NC or F68/TEL-NC solution was added to 0.8 ml of BALF and 
incubated at 37ºC. The hydrodynamic diameter was measured by DLS at various time 
points. 
 
4.2.9 Macrophage uptake 
Murine alveolar macrophages (MH-S, ATCC) were cultured. 10 mM of 
F127/TEL-NC, F68/TEL-NC, or TEL-FD was added to the cells and incubated for 2 
hours at 37ºC. Cells were detached using cell scrapers and centrifuged at XX. The 
supernatant was removed and the cells were resuspended in pH 3 MeOH to extract TEL. 
The cells were lysed in a bullet blender at XX conditions. The homogenates were 
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centrifuged at 21130xg for 10 minutes and the supernatant was collected. TEL 
concentration was measured via a spectrofluorphotometer as described above.  
 
4.2.10 Measurement of [Ca2+]i in pulmonary artery smooth muscle cells 
Primary (pulmonary artery smooth muscle cells) PASMCs were isolated from rats 
as previously described [150]. Briefly the heart and lung were excised and transferred to 
a petri dish with HEPES-buffered saline solution (HBS). The intrapulmonary arteries 
were isolated and the tissue was digested for 20 min at 37ºC in reduced Ca2+ HBS 
containing collagenase (type I, 1750 U/ml), papain (9.5 U/ml), bovine serum albumin (2 
mg/ml), and dithiothreitol (1 mM). Individual smooth muscle cells were collected and the 
cell suspension was filtered.  Cells were cultured in Ham's F-12 media supplemented 
with 0.5% fetal calf serum and 1% penicillin-streptomycin for 24–48 h.   
[Ca2+] was measured as previously described [151]. Briefly, PASMCs were plated 
at 50–60% confluence on glass coverslips and loaded with 5 μM Fura 2-AM for 1 h at 
37°C before being placed in a temperature-controlled (37°C) laminar flow chamber in a 
live cell Ca2+ imaging system. Cells loaded in the flow chamber were perfused with 
warmed modified Krebs solution and bubbled with 16% O2 gas at 37°C. The flow 
chamber and perfusates were maintained at 37°C. At the beginning of each experiment, 
cells were perfused for 15 min to allow for establishment of stable baseline. [Ca2+]i was 
calculated from the F340/F380 of Ca
2+ calibration solutions. Cells were pretreated with PBS 





4.2.11 Measurement of fibronectin content 
Primary pulmonary fibroblasts were isolated and cultured as previously described 
[152]. The lungs were harvested, minced with a razor blade and incubated in DMEM F-
12 media (Gibco) containing collagenase (type I, 2 mg/ml) at 37ºC for 30 minutes. The 
resulting cell suspension was washed with DMEM F-12 media supplemented with 15% 
FBS and 1x penicillin/streptomycin, centrifuged to collect cells and transferred to a 
culture flask. For the fibronectin measurement, the cells were incubated with 5 ng of 
TGF-for 1 hour before TEL treatment. 25 m of F127/TEL-NC or TEL-FD was added 
to the cells and exposure lasted 24 hours. Fibronectin content was measured via Western 
blot. Membranes were incubated with the primary antibody for 1 hour at room 




Statistical significance between treatment groups was determined via a two-tailed 
Student’s t test, assuming unequal variances. Comparisons between multiple groups were 
determined using one-way analysis of variance (ANOVA) with Tukey’s post hoc test. 
Calculations were performed using GraphPad Prism software. P values less than 0.05 





4.3.1 Preparation and characterization of polymer-based NP 
We first attempted to encapsulate TEL in PLGA-PEG via a single emulsion 
method using the small molecule CHA as an emulsifier. We have previous used CHA to 
load various hydrophobic drugs in PLGA NP [115, 153]. While this method produced 
small NP (133 nm) with a low PDI of 0.06 and near neutral charge (-6 mV), the drug 
loading was very poor, less than 1% (Table 4.1). We also tested various polymer and 
drug concentrations, but neither of these parameters had an effect on the TEL loading. 
We next tried an alternative small molecule emulsifier, saponin, that we have previously 
used [153]. Unlike the anionic CHA, saponin is neutrally charged. Once again, the 
physicochemical characteristics of the PLGA-PEG NP produced with saponin were 
positive with an average size of 178 nm, PDI of 0.1 and -potential of -5.3 mV; however, 
while saponin improved the drug loading compared with CHA, the average drug loading 
achieved was only 2.3% (Table 4.1). We next altered the polymer composition in an 
attempt to increase the drug loading. We tested a blend of unPEGylated and PEGylated 
PLGA (PLGA/PLGA-PEG), PLA-PEG, and a blend of unPEGylated and PEGylated 
PLA (PLA/PLA-PEG). The blending approach for both PLA and PLGA resulted in the 
highest drug loadings; however, we were still unable to achieve TEL drug loading > 4% 
(Table 4.2).  
 As an alternative to the conventional emulsion method, we also investigated 
whether bridging the TEL and polymer via chelation with zinc would improve the drug 
loading in PLGA-PEG NP. It has previously been shown that addition of zinc improves 
the loading of phosphate drugs in PLGA NP likely by forming an ionic bridge between 
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the terminal carboxyl groups on the polymer and the phosphate groups on the drugs [154-
156]. TEL also has a carboxyl group, thus we hypothesized that the zinc may interact 
with the carboxyl groups on both the drug and polymer. For this method we formulated 
the NP via a solvent diffusion method as opposed to an emulsion method. The 
physicochemical characteristics are displayed in Table 4.3. This method produced small 
NP with diameter around 110 nm with PDI < 0.1 and a near neutral -potential; however, 
the zinc chelation provided little improvement to the drug loading (~1%). Further, 
increasing the ZnCl concentration had no effect on the drug loading (Figure 4.1).   
 
4.3.2 TEL-NC formulation and physicochemical properties 
Due to the inability to achieve sufficient drug loading of TEL in polymeric-based 
NP, we instead pursued an alternative approach drug nanocrystals. Adapting a method 
previously used to produce curcumin NC [78], we formulated telmisartan nanocrystals 
(TEL-NC) using a combined bottom up and top down approach by first creating a film 
with the drug and stabilizer followed by hydration and high powered probe sonication. 
We developed two TEL-NC formulations with Pluronic F127 (F127/TEL-NC) or 
Pluronic F68 (F68/TEL-NC) as the stabilizer.  
The average hydrodynamic diameters measured by dynamic light scattering 
(DLS) were ~100 nm for F127/TEL-NC and ~250 nm for F68/TEL-NC (Table 4.4). TEM 
revealed that both NC formulations were rod-shaped, but the (F68/TEL-NC were larger 
in size than the F127/TEL-NC (Figure 4.2A and 4.2B), in agreement with the DLS 
results. Size measurements of an aqueous suspension of free drug (TEL-FD) by both DLS 
and TEM revealed larger than micron size aggregates (Table 4.4 and Figure 4.2C). These 
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findings suggest that F127 stabilized the surface of NC during formulation better than 
F68. To confirm the colloidal stability in a physiologically relevant environment, we 
measured hydrodynamic diameter over time via DLS of the F127/TEL-NC and F68/TEL-
NC formulations in murine BALF at 37ºC. The hydrodynamic diameter of the F127/TEL-
NC remained stable for at least 24 h, whereas F68/TEL-NC rapidly aggregated (> 1000 
nm) in the same conditions (Figure 4.2D). Further, the F127/TEL-NC remained stable in 
aqueous conditions for at least 25 days as indicated by little change in the hydrodynamic 
diameter and PDI during that period of time (Figure 4.2E).  
 
4.3.3 Alveolar macrophage uptake  
Additionally, we investigated the effect on the stabilizer on the ability to avoid 
clearance by mouse alveolar macrophages. We found that ~10- and 4-fold more drug was 
uptaken in mouse alveolar macrophages in vitro when administered as TEL-FD and 
F68/TEL-NC compared with F127/TEL-NC, respectively (Figure 4.3). Based on these 
results all subsequent studies were performed with the optimal F127/TEL-NC 
formulation. 
 
4.3.4 In vitro activity of F127/TEL-NC 
Next we confirmed that the nano-formulation process did not impact the drug’s 
intrinsic properties. We first tested the in vitro activity of F127/TEL-NC in primary 
pulmonary artery smooth muscle cells (PASMC) isolated from rats. Angiotensin II (ANG 
II) binding to the AT1R causes vasoconstriction and a transient elevation of intracellular 
calcium (iCa2+) levels, which is inhibited by ARB [157, 158]. Thus, drug activity can be 
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determined by measuring iCa2+ concentration in response to ANG II exposure following a 
pretreatment of ARB. Cells exposed to vehicle solutions, including F127 or PBS alone, 
exhibited a sharp increase of iCa2+ levels in response to ANG II (Figure 4.4A). In 
contrast, TEL either dosed as F127/TEL-NC or free drug, effectively blocked the 
elevation of iCa2+ (Figures 4.4B and 4.4C), suggesting that the drug activity was retained 
after NC formulation.  
 
4.3.5 Antagonism of TGF- expression by F127/TEL-NC 
TGF- is a pro-fibrotic protein that induces expression of matrix protein 
fibronectin in fibroblasts [159, 160], a hallmark of pathogenesis in lung injury [161, 162]. 
We thus investigated the effect of F127/TEL-NC on the TGF--dependent fibronectin 
expression in isolated primary mouse lung fibroblasts. As shown in Figure 4.5, we found 
that both TEL-FD and F127/TEL-NC reversed fibronectin expression induced by TGF- 
signaling (right, p<0.05). Of note, the media control exhibited some level of fibronectin 
expression mediated by supplemental TGF- required for maintaining fibroblast cell 
viability in vitro, which was reversed by both TEL-FD and F127/TEL-NC (left, p<0.05), 





Here we engineered a nanocrystal formulation of TEL suitable for pulmonary 
delivery (F127/TEL-NC). We demonstrated that the optimized NC formulation remained 
stable in a physiologically relevant environment, evaded clearance via alveolar 
macrophages and maintained the intrinsic drug properties. We first attempted to 
encapsulate TEL in PLGA NP; however, despite testing multiple parameters and methods 
we were unable to achieve significant drug loading. Fortunately the very poor water 
solubility of TEL allowed us to purse an alternative approach. Further, the F127/TEL-NC 
formulation has significant advantages over polymer-based NP for pulmonary 
administration. The F127/TEL-NC are solely composed of generally regarded as safe 
(GRAS) materials, specifically pure drug and allow for high drug loading with limited 
excipients since the particles are composed solely of drug and Pluronic. The F127/TEL-
NC formulation has significant advantages compared to free drug and drug formulated in 
polymer-based nanoparticles for pulmonary administration. The F127/TEL-NC are 
composed solely of TEL and Pluronic F127 both of which are FDA approved products. 
F127 is a Generally Regarded as Safe (GRAS) material and is widely found in in 
pharmaceutical products [79, 163]. Further, since the formulation is solely composed of 
drug and F127 concern over accumulation and potential toxicity of carrier polymers with 
repeated administrations is eliminated.  
Importantly, the nanonization process did not affect the intrinsic activity of the 
drug. Nanonization especially of hydrophobic drugs has become widely used in industry. 
In general, this process increases the particulate surface area to volume ratio which 
results in improved solubility and thus bioavailability of the drug. There are many drug 
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nanocrystals currently manufactured and used in the clinic or being tested in clinical trials 
preclinical development [73, 76, 77]. Thus, feasibility for scale up and reproducible 
manufacture of new NC are promising. Further, nanosuspensions can be readily 
nebulized as an aerosol for pulmonary delivery [73]. A nanosuspension composed of the 
corticosteroid budesonide was able to be nebulized and the size distribution was not 
affected by nebulization [164, 165]. More recently, a nebulized budesonide 
nanosuspension formulation was well tolerated in healthy adults in initial clinical trials 
and was nebulized faster compared to the commercially available formulation [166]. In a 
preclinical study in mice, nebulization of a nanosuspension formulation with the 
corticosteroid fluticasone exhibited dose proportional concentrations in the lungs and 
decreased systemic exposure [167]. The simplicity of the composition and the well-
established industrial practice result in lower regulatory barriers for the development of 
new NC products. 
The ability of F127/TEL-NC to retain colloidal stability in physiological fluid in 
the lung is of great importance, since aggregated NC can be cleared either via 
mucocililary clearance in the airways or alveolar macrophages in the airspace [17, 45, 
46]. We have previously determined the design criteria required for nanoparticles to 
evade both mucociliary and alveolar clearance and thus be retained longer in the lungs 
[70, 168]. We found that coating hydrophobic PLGA nanoparticles with Pluronic F127 
delayed clearance from mouse lungs thus increasing the drug residence time in the lungs. 
We have applied this same strategy to formulate NC for inhaled delivery. The F127/TEL-
NC formulation was adapted from a method to engineer NC that are capable of 
penetrating lung mucus [78]. Model curcumin NC produced with F127 but not those with 
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F68 were capable of diffusing in sputum from cystic fibrosis patients and also uniformly 
distributed along the mucus coated airways in mice. Unfortunately, we were unable to 
evaluate the mucus penetrating capability of our F127/TEL-NC formulation. While TEL 
possesses intrinsic fluorescence, the spectrum (300/360 nm) is in the ultraviolet region 
[169] and overlaps with the mucus autofluorescence. Further, conjugation of a 
fluorophore to the drug could potentially alter the drug properties (i.e. hydrophobicity) 
and would significantly increase the molecular weight of the compound both of which 
could impact the nanocrystal formulation. However, the same properties that make 
nanoparticles muco-inert (i.e. dense surface PEGylation) also prevent uptake and thus 
clearance via alveolar macrophages [170, 171]. In agreement with previous studies [172, 
173], we showed that the F127 coating minimized drug uptake by mouse alveolar 
macrophages compared with F68 and a free drug suspension.  
The difficulties in effectively encapsulating TEL in PLGA NP were unexpected. 
We have previously formulated biodegradable polymer-based particles with various 
hydrophobic drugs including paclitaxel [115, 174], curcumin [153], BPTES [175], and 
etoposide [176]. Further, we have successfully employed zinc chelation to load drugs in 
PLGA NP [70, 156]. However, in this case the zinc was used to transform water soluble 
drug with a phosphate group into a hydrophobic complex and thus resulted in improved 
drug loading [70, 154-156]. TEL is highly lipophilic and while it is extremely insoluble 
in water, the solubility of TEL is pH dependent and it is soluble in most strong acids and 
bases [177]. Due to the presence of a carboxyl group TEL is a weak acid with a pKa of 
4.45. Thus it is possible that TEL and PLGA (or PLA) which also possess carboxyl 




We engineered a nanocrystal formulation of the angiotensin receptor blocker, 
telmisartan, for the local treatment of COPD composed solely of drug and a GRAS 
stabilizer. The F127/TEL-NC were stable both in physiologically relevant conditions and 
in a water suspension at room temperature. Further, the F127 coating inhibited 
macrophage uptake. Importantly the formulation process did not affect the intrinsic drug 




Figure 4.1. The effect of zinc chloride concentration on 
telmisartan drug loading in PLGA-PEG nanoparticles. 




F127/TEL-NC TEL-FD F68/TEL-NC A                 B              C  
D                          E   
                     
Figure 4.2 TEL-NC formulation and characterization. Representative TEM 
images of (A) F127/TEL-NC, (B) F68/TEL-NC and (C) free drug (TEL-FD) 
(scale bar = 500 nm). (D) Colloidal stability of F127/TEL-NC and F68/TEL-
NC in murine bronchial alveolar lavage fluid (BALF) at 37°C. (E) Colloidal 
stability of F127/TEL-NC suspension in water at room temperature over time. 
Error bars represent standard error of the mean.*Denotes statistically 




Figure 4.3. Uptake of telmisartan formulations in mouse 
alveolar macrophages. MH-S cells were incubated with 10 
mM of F127/TEL-NC, F68/TEL-NC or TEL-FD for 2 hours. 
Drug concentration was measured in cell lysates. Error bars 
represent standard error of the mean. *Denotes statistically 




Figure 4.4. F127/TEL-NC antagonizes ANGII binding to ATR1. PASMC were 
pretreated with PBS or different dosing formulations of TEL for 30 min prior to 
exposure to ANG II. Representative traces of mean iCa2+ concentration in response to 
ANG II (n = 25 cells each) for (A) vehicle controls and (B) TEL-FD and F127/TEL-
NC. (C) Quantified change in iCa2+ concentration after the pretreatment with TEL-FD 
and F127/TEL-NC. Error bars represent standard error of the mean.*Denotes 
statistically significant differences (p < 0.01)  
A                     B          C 





Figure 4.5. Inhibition of TGF--dependent fibronectin 
expression in mouse primary lung fibroblasts. Effect of TEL-
FD and F127/TEL-NC (at 25 mM TEL concentration) on TGF-
 expression in media alone (left) and in the presence of 
exogenous TGF-right. Error bars represent the standard 
error of the mean. *Denotes statistically significant differences 








Table 4.1 Charaterization of biodegradable telmisartan nanoparticles produced by 
the emulsion method: effect of emulsifier 








0.5% CHA 133 ± 6 0.06 -6.0 ± 1.7 0.4 
PLGA-
PEG5k 
0.5% saponin 178 ± 22 0.10 -5.3 ± 1.6 2.3 
a Hydrodynamic diameter and polydispersity index (PDI) measured by dynamic 
light scattering. 




   
Table 4.2 Charaterization of biodegradable telmisartan nanoparticles produced by 
the emulsion method: effect of polymer 






PLGA-PEG5k 10 178 ± 2 0.10 -5.3 ± 1.6 2.3 
PLGA + 
PLGA-PEG5k 
5 151 ± 13 0.07 -9.0 ± 0.8 3.2 
PLA-PEG5k 10 184 ± 9 0.10 -6.0 ± 0.6 2.1 
PLA + PLA-
PEG5k 
5 196 ± 13 0.06 -8.2 ± 0.5 2.8 
a Hydrodynamic diameter and polydispersity index (PDI) measured by dynamic 
light scattering. 







Table 4.3. Charaterization of biodegradable telmisartan nanoparticles 









25 116 ± 2 0.07 -6.4 ± 1.0 1.1 
62.5 114 ± 3 0.08 -7.5 ± 0.7 1.2 
125 111 ± 3 0.08 -12 ± 4 1.1 
250 101 ± 3 0.09 -9.6 ± 1.3 1.4 
a Hydrodynamic diameter and polydispersity index (PDI) measured 
by dynamic light scattering. 
















F127/TEL-NC 110 ± 7 0.2 180 ± 4 33 ± 1 -2.0 ± 0.2 
F68/TEL-NC 250 ± 50 0.2 280 ± 8 44 ± 1 -5.0 ± 0.2 
TEL-FD 1300 ± 50 0.4 -- -- -- 
Table 4.4. Physicochemical properties of telmisatan nanocrystals 
a Measured by dynamic light scattering. 
b Measured from TEM images. 




5. Efficacy of telmisartan nanocrystals in COPD animal models 
5.1 Introduction  
Chronic obstructive pulmonary disease (COPD) is currently the third leading 
cause of death in the United States [1] with continuously increasing mortality [2]. COPD 
is a progressive disease primarily caused by cigarette smoke (CS) as well as other inhaled 
pollutants [3]. The disease is characterized by chronic, irreversible obstruction of airflow 
from the lung, which is resulted from airspace enlargement (i.e. emphysema), as well as 
airway inflammation and remodeling [4]. Common symptoms of COPD are dyspnea, 
chronic cough, and sputum production [4]. Current treatment options fail to treat the 
underlying causes of disease and only provide symptom relief [10]. Smoking cessation 
influences the nature history of disease and is the most effective way to limit disease 
progression [11]. The primary pharmacological treatments for COPD are inhaled 
bronchodilators, such as -agonists and muscarinic antagonists, and corticosteroids [4, 
12]. Thus new therapeutic options that intervene in the natural history of the disease are 
sorely needed.  
 Appropriate preclinical models are critical to properly evaluate the effect of new 
therapeutics. There are multiple methods to generate COPD animal models, especially in 
mice, and these models are typically categorized as induced or genetic. CS exposure is 
the most widely studied induced model [89-91]. This is logical given that the primary risk 
factor for COPD development and progression in humans is tobacco smoke [3]. The 
COPD-like pathology is established by daily CS exposure for an extended period of time, 
typically weeks to months, either via whole body or nose-only exposure systems [90]. 
Mice exposed to chronic CS develop airspace enlargement, small airway remodeling, 
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chronic inflammation, and elevated oxidative stress [92].  However, a major limitation of 
the smoke exposure models is that regardless of the method parameters, the pathology of 
severe disease in humans cannot be replicated [89]. Specifically, while CS exposure can 
produce the emphysema phenotype and inflammation, mucus hypersecretion and airway 
obstruction are not established despite the presence of goblet cell metaplasia and airway 
remodeling [92]. A common genetic model is the tight skin (TSK) mouse which has a 
heterozygous duplication of the fibrilin-1 gene [94]. This mutation results in excess 
matrix deposition with fibrosis in the skin as well as impaired alveolar septation that 
progresses to airspace enlargement [96, 97]. This phenotype is at least partially attributed 
to cell death as a result of oxidative stress [98]. However, inflammation has not been 
implicated in the pathology [99]. 
Here, we have developed an inhalable nanocrystal (NC) formulation with the 
angiotensin receptor blocker (ARB) telmisartan (TEL; TEL-NC) for the localized 
treatment of COPD. We demonstrated that the inhalable nano-formulation enhanced the 
efficacy of TEL by improving lung drug levels over time compared with oral 
administration. We also anticipate that the inhalable ARB will allow for reduced dose 
and/or dosing frequency compared to the conventional oral dosage form. Our studies will 
ultimately provide proof-of-concept evidence that therapeutics targeting the TGF- β 
pathway can be reliably delivered by inhalation to the airway and airspace compartments 







5.2.1 Animals  
All animal protocols were approved by the Institutional Animal Care and Use 
Committee at the Johns Hopkins Medical Institutions. All mice were allowed to 
acclimate for 1-2 weeks before handling, with access to food and water ad libitum 
throughout the experiments. Female C57/B6 6-8 weeks of age were obtained from 
Harlan. TSK mice were obtained from Jackson Laboratory (Bar Harbor, ME) and bred 
with C57/B6 wild type mice [98]. 
 
5.2.2 Formulation and characterization of F127/TEL-NC 
TEL and Pluronic F127 were dissolved in 2 ml of chloroform at a 1:4 mass ratio. 
The chloroform was rapidly evaporated with a nitrogen gas stream to create a film. The 
film was further dried via vacuum overnight. The film was hydrated with ultrapure water 
and incubated for 20 minutes at room temperature followed by bath sonication for 10 
minutes. The suspension was further homogenized with a Vibra-CellTM VCX-500 probe 
sonicator for 30 minutes with a pulse of 1 second on 1 second off at 100% amplitude. The 
resultant suspension was centrifuged at 2000 rpm for 5 minutes to remove any large 
particulates. F127/TEL-NC were collected via centrifugation at 21130xg for 10 minutes 
and were resuspended in ultrapure water. To measure TEL concentration, F127/TEL-NC 
were dissolved in methanol and the concentration was measured using a 
spectrofluorophotometer at excitation 300 and emission 360 nm with a slit width of 3 for 
both the excitation and emission. The TEL free drug (TEL-FD) was prepared by crushing 
Micardis® tablets into a powder and creating a suspension in water. The hydrodynamic 
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diameter of F127/TEL-NC in water was measured via dynamic light scattering (DLS) 
with a Zetasizer Nano ZS.  
 
5.2.3 Pharmacokinetics  
C57/B6 mice were anesthetized with an intraperitoneal injection of avertin and 
administered 3 mg/kg of F127/TEL-NC or TEL-FD via intratracheal aspiration or TEL-
FD via oral gavage. Mice were sacrificed and various time points and lungs and plasma 
were collected (n=5 per time point). To measure the TEL concentration in the lungs, the 
tissues were dried via lyophilzation and then crushed to a powder with a mortar and 
pestle. The drug was extracted into 1 ml of 50:50 methanol and DMSO at pH 3 and 200 
l of acetonitrile following homogenization with a bullet blender for 10 minutes. The 
samples were centrifuged at 21130xg for 10 minutes, the supernatant was collected and 
was diluted 10-fold with the methanol/DMSO solvent mixture. For the plasma samples, 
0.2 ml of acetonitrile was added to precipitate the serum proteins. The samples were 
centrifuged at 21130xg for 10 minutes, the supernatant was collected and was diluted 10-
fold with methanol/DMSO solvent mixture. The drug concentration in both lung and 
plasma samples was measured with a spectrofluorophotometer (Shimadzu) at an 
excitation of 300 and emission of 385 nm with a slit width of 3 for both excitation and 
emission. 
 
5.2.4 Cigarette smoke exposure 
C57/B6 mice 6-8 weeks old were divided into three groups with 6 mice per group. 
Control mice were exposed to room air (RA) only. The animals exposed to CS were 
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either left untreated or were administered 1 mg/kg of F127/TEL-NC via intratracheal 
aspiration twice a week for a month concomitantly with the CS exposure. CS exposure 
was carried out (5 hours per day, 5 days per week) by burning 2R4F reference cigarettes 
(University of Kentucky, Louisville, Kentucky, USA) using a smoking machine (Model 
TE-10; Teague Enterprises). Cigarettes were smoked with standard puffs of 35 ml 
volume of 2-second duration. The average concentration of total suspended particulates 
and carbon monoxide was 90 mg/m3 and 350 ppm, respectively, and was monitored on a 
daily basis [85, 178]. 
 
5.2.5 TSK model 
Treatment of TSK mice was initiated at 2 weeks of age. Mice were left untreated 
or administered 1 mg/kg of TEL-FD via oral gavage daily or 1 mg/kg of F127/TEL-NC 
via intratracheal aspiration twice a week for two weeks. Wild type (WT) litter mates were 
used as controls. All animals were sacrificed at 4 weeks of age except the control TSK 
group that was sacrificed at 2 weeks of age.  
 
5.2.6 Morphometry 
For histologic and morphometric analyses, mouse lungs were inflated with 
agarose and fixed with 4% PFA. The lungs were equilibrated in cold 4% PFA overnight, 
sectioned, and then embedded in paraffin wax. Sections were cut at 5 m and either 
stained with H&E or processed for immunohistochemistry. Mean linear intercept 
measurements were performed on H&E-stained sections taken at intervals throughout the 
lungs. Ten to fifteen images per slide were acquired at 20x magnification. Mean linear 
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intercepts were assessed by automated morphometry with a macro-operation performed 
by Metamorph Imaging Software (Universal Imaging, Molecular Devices).  
 
5.2.7 Immunohistochemistry.  
Tissue sections were deparaffinized and rehydrated in an ethanol series. Antigens 
were retrieved by incubation in boiling citrate buffer (10 mM, pH 6.0) for 10 minutes. 
Sections were blocked for nonspecific binding with 3% normal serum from chicken and 
incubated with the primary antibodies for 1 hour at room temperature followed by 
incubation with the primary antibody overnight at 4°C. Slides were washed with 
phosphate buffered saline with Tween 20 (PBST). For phosphorylated Smad2 (pSmad2) 
staining, the pSmad2/3 antibody (Maine Medical Center Research Institute) was diluted 
1:2000 and the staining was developed with the anti-rabbit UltraVision detection kit 
(Thermo Scientific). For 8-hydroxyguanosine (8-OHdG) staining, the antibody (Novus 
Biologicals) was diluted 1:200, incubated with the secondary antibody (Vector 
Laboratories), and staining was detected with the ABC system kit from Vector 
Laboratories. Quantitative immunohistochemistry was performed by normalizing staining 
to tissue area using Metamorph software. Images were captured with  Nikon Elements on 
a Nikon Upright Biological Microscope Model Eclipse 80i.  
 
5.2.8 Measurement of inflammatory cells 
Bronchial alveolar lavage fluid (BALF) was collected by washing the lungs with 1 
ml of PBS three times. Cells were collected via centrifugation. The cells were fixed in 
PFA and were counted with a hemocytometer. Differential cell counting samples were 
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prepared as follows. Cells were fixed onto microscope slides via cytospins and allowed to 
dry overnight. The cells were stained with Diff-Quik stain. Cells were imaged with a 
Nikkon E-600 microscope and a total of 5-10 images were take per sample. A trained, 
blinded participant classified each cell in the images as macrophage, neutrophil, 
lymphocyte, or other. A minimum of 300 cells were classified per sample. 
 
5.2.9 Statistics 
Comparisons between multiple groups were determined using one-way analysis 
of variance (ANOVA) with Tukey’s post hoc test. Calculations were performed using 
GraphPad Prism software. P values less than 0.05 were considered significant.  
 
5.3 Results  
5.3.1 Pharmacokinetics 
A primary advantage of local drug delivery is to increase the drug exposure at the 
site of injury and potentially limit the systemic drug exposure. We hypothesized that the 
daily oral dosing regimen may not provide a therapeutically effective drug concentration 
in the lung, and that the inhaled F127/TEL-NC formulation would provide improved 
pulmonary drug concentration compared to systemically administered TEL-FD. We thus 
assessed the lung PK of inhaled F127/TEL-NC compared with that of TEL-FD 
administered via an oral gavage. Intratracheally administered TEL F127/TEL-NC 
significantly improved the local drug concentration over time up to 24 h compared to the 
orally administered TEL-FD (Figure 1A). The AUC from locally administered 
F127/TEL-NC was 4.6-fold greater than the oral gavage free drug TEL. Further, we 
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compared the lung PK of the F127/TEL-NC to intratracheally administered TEL-FD and 
found that the drug concentration from F127/TEL-NC was significantly higher at all time 
points with a 7–fold higher AUC. We also measured the drug plasma concentration of the 
oral TEL-FD, inhaled TEL-FD and inhaled F127/TEL-NC (Figure 1B). Interestingly, the 
initial plasma concentration of the intratracheally administered F127/TEL-NC was higher 
than that of the other two dosing schemes.  
5.3.2 Protective effect of inhaled F127/TEL-NC in an acute model of CS-exposed lung 
injury 
  We next investigated the effect of inhaled F127/TEL-NC in the lungs of an acute 
model of CS-exposure. Short term exposure (i.e. 4 weeks) of CS induced increased TGF-
 signaling as indicated by the phosphorylation of the cytoplasmic signaling molecule 
Smad2 (pSmad2) (Figure 2A, 2B; p < 0.05) [85, 179]. Intratracheal administration of 
F127/TEL-NC (1 mg/kg TEL) twice per week for four weeks, concomitantly initiated 
with CS exposure, effectively suppressed the phosphorylation of Smad2 compared with 
CS only mice (p < 0.05); the pSmad2 level of F127/TEL-NC treated CS-exposed mice 
was comparable to that of RA control mice (Figure 2A, 2B). The enhanced 8-OHdG level 
indicates that oxidative stress was also elevated by an acute CS exposure (Figures 2C, 
2D). Further, we confirmed that the acute CS exposure triggered immune cell infiltration, 
as evidenced by an increase in total inflammatory cells (Figure 3A, p < 0.05) and the 
fraction of neutrophils in BALF (Figure 3B, p < 0.05) compared to the RA control. We 
found that the acute CS-induced oxidative stress (Figures 2C, 2D) and lung inflammation 




5.3.3 Therapeutic effect of inhaled F127/TEL-NC in a transgenic mouse model of 
emphysema  
We next investigated whether inhaled F127/TEL-NC is capable of therapeutically 
attenuating TGF- signaling, and thus the subsequent pathological events. To do this, we 
utilized the TSK transgenic mouse model of emphysema. We initiated treatment of either 
daily oral administration of TEL-FD or four doses of intratracheal F127/TEL-NC at 2-
weeks of age (when airway enlargement is evident; [98]) that lasted for 2 weeks, and 
lungs were harvested at 4-weeks of age. Following intratracheal administration of 
F127/TEL-NC partial reversal of airway enlargement was achieved based on histological 
analysis (Figure 4A). Quantitatively, the airspace diameter, as indicated by the mean 
linear intercept (MLI), was significantly reduced upon intratracheal treatment with 
F127/TEL-NC compared with the TSK mice evaluated at the same time point (Figure). 
Importantly, the MLI with F127/TEL-NC treatment was statistically lower than that at 2 
weeks of age when dosing began.  
We also confirmed that F127/TEL-NC significantly decreased the pSmad2 level 
in the lungs of TSK mice (Figure 4B), indicating TGF- antagonism by the treatment. 
Additionally, the pSmad expression with F127/TEL-NC evaluated at 4 weeks was 
significantly reduced compared with that at 2 weeks of age when treatment was initiated. 
Further, inhaled F127/TEL-NC significantly reduced oxidative stress levels in the lung as 
indicated by enhanced 8-OHdG expression (Figure 4C).  In contrast, we found that the 
daily oral TEL-FD had no effect on the airspace enlargement, the elevated pSmad2 




5.4 Discussion  
There are currently no treatment options in the clinic or clinical trials that 
effectively halt progression or achieve reversal of COPD. The majority of the current pre-
clinically tested treatments only show protection and not a therapeutic effect. Here, in 
addition to achieving protection in an acute CS model of lung injury, we also show a 
therapeutic reversal of lung damage in the transgenic TSK model following treatment 
with the inhaled F127/TEL-NC. This effect was only achieved with the inhaled 
nanocrystal formulation as opposed to the free drug administered orally.  
COPD is a complex heterogeneous disease characterized by obstructed airflow due 
chronic inflammation and alveolar destruction. Thus, therapies to combat inflammation 
and/or induce tissue regeneration are currently being investigated. The reduction and/or 
elimination of inflammation is considered one of the primary approaches to prevent and 
potentially reverse disease progression [180]. A gamut of anti-inflammatory therapies 
targeting specific inflammatory mediators and oxidative stress as well as broad-spectrum 
inflammation are currently being extensively studied [181]. The basic pathophysiological 
and molecular mechanisms of the inflammation in COPD are still poorly understood, and 
thus pose a significant challenge to the discovery and development of new therapies to 
halt or reverse the progression of disease and ultimately reduce mortality [180]. Because 
of the significant risk in development of new agents, the repurposing of agents already 
approved for other indications is an attractive strategy.   
Alternatively, strategies to regenerate destroyed tissue are being studied as well 
[182-184]. Recently, liver growth factor was shown to actually reverse airspace 
enlargement as well as ameliorate lung inflammation after establishment of emphysema 
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in a CS-exposure mouse model [185, 186]. Further, stem cell therapies are currently in 
clinical trials to treat COPD and preliminary results show improved lung function [187] 
and anti-inflammatory effects [188].  
Here, we focus on the TFG- pathway which has been implicated in the 
pathogenesis of COPD and has been shown to be elevated in the lungs of COPD patients. 
In particular, TGF- dysregulation is associated with inflammation, oxidative stress, and 
cell death [85], and thus it is a very attractive target for COPD therapy. We previously 
showed that oral administration of the ARB losartan (LOS) effectively protected the 
lungs in a chronic CS-exposure model. Here, we expanded upon the prior work by 
repurposing TEL, another ARB that is FDA approved therapy for hypertension, to treat 
COPD and engineering an inhalable nano-formulation of TEL.  
We first investigated the preventative effect of F127/TEL-NC in an acute CS 
exposure model. Although acute CS exposure is insufficient to develop the emphysema 
phenotype, we previously confirmed that only 2 weeks of exposure significantly 
increased the TGF- levels in lung lysates [85]. Alternatively, the chronic CS-induced 
emphysema models typically take 4 to 6 months to establish [90]. Further, ARBs have 
typically been delivered orally either via gavage [189-191] or administered in food or 
water [192-194] as opposed to inhalation. Thus this shorter exposure model also allowed 
us to determine the appropriate dose for pulmonary delivery. Here we confirmed that four 
weeks (i.e acute) CS-exposure induced TGF- signaling, thus validating the acute CS-
exposed model to evaluate the TGF- antagonizing effect of F127/TEL-NC. Further, 
enhanced TGF- signaling increases reactive oxygen species [195] and can promote 
inflammation [196]. Both oxidative stress and inflammatory cells were elevated by the 
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acute CS-exposure. Intratracheal F127/TEL-NC attenuated the TGF- expression as well 
as the oxidative stress and inflammation, thus suggesting that the local treatment 
effectively prevented TFG-b signaling in the lungs of an acute CS-exposed mouse model 
of lung injury.  
Next we tested the therapeutic effect of F127/TEL-NC in the TSK transgenic 
model of emphysema. Compared with chronic CS-exposed models, the TSK mouse 
model develops early and extensive emphysema, a key pathological event in the airspace 
of COPD patients, and, thus serves as a rigorous model for testing therapeutic reversal of 
established emphysema [98, 197]. TGF- signaling is elevated in TSK mice, suggesting 
that the airspace enlargement in the mouse model may be TGF--dependent [98, 198-
200]. Further, increased oxidative stress, an effector pathway for TGF-, contributes 
significantly to the airspace phenotype [98]. Thus this model was appropriate for 
preliminary studies of the therapeutic effect of F127/TEL-NC. Intratracheally 
administered F127/TEL-NC effectively suppressed TGF-expression which manifested 
in attenuation of airspace enlargement and reduced levels of oxidative stress. On the other 
hand, daily oral TEL-FD at the same dose had no effect on the lung damage and 
oxidative stress. Importantly, inhaled F127/TEL-NC not only attenuated disease 
progression, but also demonstrated partial reversal of airspace enlargement and TGF- 
expression at the end point compared with the initiation of treatment, indicating a 
therapeutic as opposed to preventative effect.  
Daily oral treatment did not resolve lung damage in the TSK model likely because 
this conventional dosing regimen did not provide a sufficient local drug concentration 
required for therapeutic reversal of established lung injury. We achieved higher local 
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drug concentrations in the lung with intratracheal F127/TEL-NC compared with both oral 
and inhaled TEL-FD. This suggests that the dose and dosing frequency can be reduced 
with inhaled F127/TEL-NC, both of which are important for user compliance. Further, 
inhalation of the TEL-FD showed no pharmacokinetic improvement compared with oral 
free drug, which indicates that inhalation alone is not sufficient to achieve higher drug 
concentration in the lungs. TEL is very hydrophobic and thus the drug aggregates can be 
cleared via mucociliary and/or macrophage clearance [45].  
 
5.5 Conclusion 
These findings suggest that intratracheally administered F127/TEL-NC, unlike 
oral daily free drug TEL-FD, can partially reverse pathologic airspace enlargement and 
also ameliorate lung injury caused by enhanced TGF- signaling. These findings 
underscore that the conventional daily oral dosing regimen may not provide a local drug 
concentration required for therapeutic reversal of established COPD lung disease. In the 












      
Figure 5.1. Pharmacokinetics of telmisartan in mouse lung 
tissue and plasma. The amount of TEL was measured in (A) the 
lung tissue and (B) the plasma over time following administration 
of F127/TEL-NC via inhalation (IT), TEL-FD administered via 
inhalation (IT), and TEL-FD administered via oral gavage (G). 
Data represents n = 5 mice per group. Error bars represent the 





A                                   B 
C                                   D 
Figure 5.2. Preventive effect of inhaled F127/TEL-NC in an acute 
model of cigarette smoke-exposed lung injury: TFG-b expression. 
(A-C) Representative images of pSmad2 stained lung sections of 
mice exposed to (A) room air (RA), (B) cigarette smoke (CS), and 
(C) CS treated with inhaled temisartan nanocrystals (CS+F127/TEL-
NC). (D) Quantification of pSmad2 staining. Data represents n = 6 
mice per group. Error bars represent the standard error of the 
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Figure 5.3. Preventive effect of inhaled F127/TEL-NC in an acute 
model of cigarette smoke-exposed lung injury: oxidative stress. (C) 
Representative images of 8-OHdG stained lung sections of mice 
exposed to (A) room air (RA), (B) cigarette smoke (CS), and (C) CS 
treated with inhaled temisartan nanocrystals (CS+F127/TEL-NC). (D) 
Quantification of 8-OHdG staining. *Denotes statistical significance 




A     B 
Figure 5.4. Preventive effect of inhaled F127/TEL-NC in an acute model of 
cigarette smoke-exposed lung injury: inflammation. (A) Total cell count in 
the BALF. (B) The percent of neutrophils in the BALF. Data represents n = 6 
mice per group. Error bars represent the standard error of the mean. *Denotes 
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Figure 5.5. Therapeutic effect of inhaled F127/TEL-NC in the transgenic TSK 
mouse model of emphysema: airspace enlargement. (A-E) Representative images 
of H&E stained lung sections of (A) wild-type (WT), (B) TSK mice at 2 weeks 
(TSK 2wk), (C) TSK mice at 4 weeks (TSK 4wk), (D) TSK treated with daily oral 
gavage of free drug (TSK 4wk+TEL-FD), and (E) TSK treated with intratracheal 
drug nanocrystals (TSK 4wk+F127/TEL-NC). (F) Quantification of mean linear 
intercept (MLI). Error bars represent the standard error of the mean. *Denotes 
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Figure 5.6. Therapeutic effect of inhaled F127/TEL-NC in the transgenic TSK 
mouse model of emphysema: TGF- expression. (A-E) Representative images of 
pSmad2 stained lung sections of (A) wild-type (WT), (B) TSK mice at 2 weeks 
(TSK 2wk), (C) TSK mice at 4 weeks (TSK 4wk), (D) TSK treated with daily oral 
gavage of free drug (TSK 4wk+TEL-FD), and (E) TSK treated with intratracheal 
drug nanocrystals (TSK 4wk+F127/TEL-NC). (F) Quantification of pSmad2 
staining. Error bars represent the standard error of the mean. *Denotes statistical 
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Figure 5.7. Therapeutic effect of inhaled F127/TEL-NC in the transgenic TSK 
mouse model of emphysema: oxidative stress. (A-E) Representative images of 8-
OHdG stained lung sections of (A) wild-type (WT), (B) TSK mice at 2 weeks (TSK 
2wk), (C) TSK mice at 4 weeks (TSK 4wk), (D) TSK treated with daily oral gavage 
of free drug (TSK 4wk+TEL-FD), and (E) TSK treated with intratracheal drug 
nanocrystals (TSK 4wk+F127/TEL-NC). (F) Quantification of 8-OHdG staining. 
Error bars represent the standard error of the mean. *Denotes statistical significance 
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